{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T02:40:49Z","timestamp":1789094449132,"version":"build-2803163510"},"reference-count":313,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T00:00:00Z","timestamp":1765929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T00:00:00Z","timestamp":1765929600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clinic Rev Allerg Immunol"],"DOI":"10.1007\/s12016-025-09115-5","type":"journal-article","created":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T12:11:11Z","timestamp":1765973471000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Pathophysiologic Mechanisms and Targeted Treatments Associated with the Nervous System in Cutaneous Allergic Diseases"],"prefix":"10.1007","volume":"68","author":[{"given":"Hantian","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiyi","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xian","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linghong","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,17]]},"reference":[{"key":"9115_CR1","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1038\/nn.3144","volume":"15","author":"IM Chiu","year":"2012","unstructured":"Chiu IM, von Hehn CA, Woolf CJ (2012) Neurogenic inflammation and the peripheral nervous system in host defense and immunopathology. Nat Neurosci 15:1063\u20131067. https:\/\/doi.org\/10.1038\/nn.3144","journal-title":"Nat Neurosci"},{"key":"9115_CR2","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1002\/eji.202048812","volume":"51","author":"CSN Klose","year":"2021","unstructured":"Klose CSN, Veiga-Fernandes H (2021) Neuroimmune interactions in peripheral tissues. Eur J Immunol 51:1602\u20131614. https:\/\/doi.org\/10.1002\/eji.202048812","journal-title":"Eur J Immunol"},{"key":"9115_CR3","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1146\/annurev-neuro-111020-105359","volume":"45","author":"RGJ Klein Wolterink","year":"2022","unstructured":"Klein Wolterink RGJ, Wu GS, Chiu IM, Veiga-Fernandes H (2022) Neuroimmune interactions in peripheral organs. Annu Rev Neurosci 45:339\u2013360. https:\/\/doi.org\/10.1146\/annurev-neuro-111020-105359","journal-title":"Annu Rev Neurosci"},{"key":"9115_CR4","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1016\/j.jaci.2023.03.013","volume":"151","author":"AW Liu","year":"2023","unstructured":"Liu AW, Gillis JE, Sumpter TL, Kaplan DH (2023) Neuroimmune interactions in atopic and allergic contact dermatitis. J Allergy Clin Immunol 151:1169\u20131177. https:\/\/doi.org\/10.1016\/j.jaci.2023.03.013","journal-title":"J Allergy Clin Immunol"},{"key":"9115_CR5","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/nn.3881","volume":"18","author":"D Usoskin","year":"2015","unstructured":"Usoskin D et al (2015) Unbiased classification of sensory neuron types by large-scale single-cell RNA sequencing. Nat Neurosci 18:145\u2013153. https:\/\/doi.org\/10.1038\/nn.3881","journal-title":"Nat Neurosci"},{"key":"9115_CR6","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.jaad.2021.07.078","volume":"86","author":"N Sutaria","year":"2022","unstructured":"Sutaria N et al (2022) Itch: pathogenesis and treatment. J Am Acad Dermatol 86:17\u201334. https:\/\/doi.org\/10.1016\/j.jaad.2021.07.078","journal-title":"J Am Acad Dermatol"},{"key":"9115_CR7","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1152\/physrev.00017.2019","volume":"100","author":"F Cevikbas","year":"2020","unstructured":"Cevikbas F, Lerner EA (2020) Physiology and pathophysiology of itch. Physiol Rev 100:945\u2013982. https:\/\/doi.org\/10.1152\/physrev.00017.2019","journal-title":"Physiol Rev"},{"key":"9115_CR8","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/j.jaci.2023.10.034","volume":"153","author":"G Yosipovitch","year":"2024","unstructured":"Yosipovitch G et al (2024) Similarities and differences in peripheral itch and pain pathways in atopic dermatitis. J Allergy Clin Immunol 153:904\u2013912. https:\/\/doi.org\/10.1016\/j.jaci.2023.10.034","journal-title":"J Allergy Clin Immunol"},{"key":"9115_CR9","doi-asserted-by":"publisher","first-page":"555","DOI":"10.2340\/00015555-1353","volume":"92","author":"NQ Phan","year":"2012","unstructured":"Phan NQ, Lotts T, Antal A, Bernhard JD, St\u00e4nder S (2012) Systemic kappa opioid receptor agonists in the treatment of chronic pruritus: a literature review. Acta Derm Venereol 92:555\u2013560. https:\/\/doi.org\/10.2340\/00015555-1353","journal-title":"Acta Derm Venereol"},{"key":"9115_CR10","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.jdermsci.2007.02.002","volume":"46","author":"M Tominaga","year":"2007","unstructured":"Tominaga M, Ozawa S, Ogawa H, Takamori K (2007) A hypothetical mechanism of intraepidermal neurite formation in NC\/Nga mice with atopic dermatitis. J Dermatol Sci 46:199\u2013210. https:\/\/doi.org\/10.1016\/j.jdermsci.2007.02.002","journal-title":"J Dermatol Sci"},{"key":"9115_CR11","doi-asserted-by":"publisher","first-page":"419","DOI":"10.2147\/ccid.S257647","volume":"13","author":"K Bodoor","year":"2020","unstructured":"Bodoor K et al (2020) IL-33\/13 axis and IL-4\/31 axis play distinct roles in inflammatory process and itch in psoriasis and atopic dermatitis. Clin Cosmet Investig Dermatol 13:419\u2013424. https:\/\/doi.org\/10.2147\/ccid.S257647","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"9115_CR12","doi-asserted-by":"publisher","first-page":"2982","DOI":"10.1111\/all.14791","volume":"76","author":"A Datsi","year":"2021","unstructured":"Datsi A, Steinhoff M, Ahmad F, Alam M, Buddenkotte J (2021) Interleukin-31: the itchy cytokine in inflammation and therapy. Allergy 76:2982\u20132997. https:\/\/doi.org\/10.1111\/all.14791","journal-title":"Allergy"},{"key":"9115_CR13","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1080\/1744666x.2021.1940962","volume":"17","author":"C Dubin","year":"2021","unstructured":"Dubin C, Del Duca E, Guttman-Yassky E (2021) The IL-4, IL-13 and IL-31 pathways in atopic dermatitis. Expert Rev Clin Immunol 17:835\u2013852. https:\/\/doi.org\/10.1080\/1744666x.2021.1940962","journal-title":"Expert Rev Clin Immunol"},{"key":"9115_CR14","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.jaci.2005.10.033","volume":"117","author":"E Sonkoly","year":"2006","unstructured":"Sonkoly E et al (2006) IL-31: a new link between T cells and pruritus in atopic skin inflammation. J Allergy Clin Immunol 117:411\u2013417. https:\/\/doi.org\/10.1016\/j.jaci.2005.10.033","journal-title":"J Allergy Clin Immunol"},{"key":"9115_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-25094-4","volume":"8","author":"A Takamori","year":"2018","unstructured":"Takamori A et al (2018) IL-31 is crucial for induction of pruritus, but not inflammation, in contact hypersensitivity. Sci Rep 8:6639. https:\/\/doi.org\/10.1038\/s41598-018-25094-4","journal-title":"Sci Rep"},{"key":"9115_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s10020-018-0025-6","volume":"24","author":"XY Luo","year":"2018","unstructured":"Luo XY et al (2018) OSMR gene effect on the pathogenesis of chronic autoimmune urticaria via the JAK\/STAT3 pathway. Mol Med 24:28. https:\/\/doi.org\/10.1186\/s10020-018-0025-6","journal-title":"Mol Med"},{"key":"9115_CR17","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.jaci.2013.10.048","volume":"133","author":"F Cevikbas","year":"2014","unstructured":"Cevikbas F et al (2014) A sensory neuron-expressed IL-31 receptor mediates T helper cell-dependent itch: involvement of TRPV1 and TRPA1. J Allergy Clin Immunol 133:448\u2013460. https:\/\/doi.org\/10.1016\/j.jaci.2013.10.048","journal-title":"J Allergy Clin Immunol"},{"key":"9115_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.113433","volume":"42","author":"S Takahashi","year":"2023","unstructured":"Takahashi S et al (2023) Sensory neuronal STAT3 is critical for IL-31 receptor expression and inflammatory itch. Cell Rep 42:113433. https:\/\/doi.org\/10.1016\/j.celrep.2023.113433","journal-title":"Cell Rep"},{"key":"9115_CR19","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1016\/j.jaci.2017.12.1002","volume":"141","author":"J Meng","year":"2018","unstructured":"Meng J et al (2018) New mechanism underlying IL-31-induced atopic dermatitis. J Allergy Clin Immunol 141:1677\u20131689e1678. https:\/\/doi.org\/10.1016\/j.jaci.2017.12.1002","journal-title":"J Allergy Clin Immunol"},{"key":"9115_CR20","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abi6887","volume":"8","author":"MS Fassett","year":"2023","unstructured":"Fassett MS et al (2023) IL-31-dependent neurogenic inflammation restrains cutaneous type 2 immune response in allergic dermatitis. Sci Immunol 8:eabi6887. https:\/\/doi.org\/10.1126\/sciimmunol.abi6887","journal-title":"Sci Immunol"},{"key":"9115_CR21","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1126\/science.1233765","volume":"340","author":"SK Mishra","year":"2013","unstructured":"Mishra SK, Hoon MA (2013) The cells and circuitry for itch responses in mice. Science 340:968\u2013971. https:\/\/doi.org\/10.1126\/science.1233765","journal-title":"Science"},{"key":"9115_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.696784","volume":"12","author":"J Meng","year":"2021","unstructured":"Meng J et al (2021) Th2 modulation of transient receptor potential channels: an unmet therapeutic intervention for atopic dermatitis. Front Immunol 12:696784. https:\/\/doi.org\/10.3389\/fimmu.2021.696784","journal-title":"Front Immunol"},{"key":"9115_CR23","doi-asserted-by":"publisher","unstructured":"Xu J et al (2020) The cytokine TGF-\u03b2 induces interleukin-31 expression from dermal dendritic cells to activate sensory neurons and stimulate wound itching. Immunity 53:371\u2013383.e5. https:\/\/doi.org\/10.1016\/j.immuni.2020.06.023","DOI":"10.1016\/j.immuni.2020.06.023"},{"key":"9115_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2023.108348","volume":"242","author":"Y G\u00e4rtner","year":"2023","unstructured":"G\u00e4rtner Y, Bitar L, Zipp F, Vogelaar CF (2023) Interleukin-4 as a therapeutic target. Pharmacol Ther 242:108348. https:\/\/doi.org\/10.1016\/j.pharmthera.2023.108348","journal-title":"Pharmacol Ther"},{"key":"9115_CR25","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1111\/exd.14034","volume":"28","author":"M Campion","year":"2019","unstructured":"Campion M et al (2019) Interleukin-4 and interleukin-13 evoke scratching behaviour in mice. Exp Dermatol 28:1501\u20131504. https:\/\/doi.org\/10.1111\/exd.14034","journal-title":"Exp Dermatol"},{"key":"9115_CR26","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9113741","author":"M Furue","year":"2020","unstructured":"Furue M (2020) Regulation of skin barrier function via competition between AHR axis versus IL-13\/IL-4\u2012JAK\u2012STAT6\/STAT3 axis: pathogenic and therapeutic implications in atopic dermatitis. J Clin Med. https:\/\/doi.org\/10.3390\/jcm9113741","journal-title":"J Clin Med"},{"key":"9115_CR27","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.bbi.2021.08.211","volume":"98","author":"S Xiao","year":"2021","unstructured":"Xiao S et al (2021) Innate immune regulates cutaneous sensory IL-13 receptor alpha 2 to promote atopic dermatitis. Brain Behav Immun 98:28\u201339. https:\/\/doi.org\/10.1016\/j.bbi.2021.08.211","journal-title":"Brain Behav Immun"},{"key":"9115_CR28","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.cell.2017.08.006","volume":"171","author":"LK Oetjen","year":"2017","unstructured":"Oetjen LK et al (2017) Sensory neurons Co-opt classical immune signaling pathways to mediate chronic itch. Cell 171:217\u2013228e213. https:\/\/doi.org\/10.1016\/j.cell.2017.08.006","journal-title":"Cell"},{"key":"9115_CR29","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1068260","volume":"13","author":"IH Huang","year":"2022","unstructured":"Huang IH, Chung WH, Wu PC, Chen CB (2022) Jak-STAT signaling pathway in the pathogenesis of atopic dermatitis: an updated review. Front Immunol 13:1068260. https:\/\/doi.org\/10.3389\/fimmu.2022.1068260","journal-title":"Front Immunol"},{"key":"9115_CR30","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24010420","author":"O Mahmoud","year":"2022","unstructured":"Mahmoud O, Soares GB, Yosipovitch G (2022) Transient receptor potential channels and itch. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms24010420","journal-title":"Int J Mol Sci"},{"key":"9115_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01464-x","volume":"8","author":"M Zhang","year":"2023","unstructured":"Zhang M et al (2023) TRP (transient receptor potential) ion channel family: structures, biological functions and therapeutic interventions for diseases. Signal Transduct Target Ther 8:261. https:\/\/doi.org\/10.1038\/s41392-023-01464-x","journal-title":"Signal Transduct Target Ther"},{"key":"9115_CR32","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/sj.bjp.0707219","volume":"151","author":"F Fujita","year":"2007","unstructured":"Fujita F, Moriyama T, Higashi T, Shima A, Tominaga M (2007) Methyl p-hydroxybenzoate causes pain sensation through activation of TRPA1 channels. Br J Pharmacol 151:153\u2013160. https:\/\/doi.org\/10.1038\/sj.bjp.0707219","journal-title":"Br J Pharmacol"},{"key":"9115_CR33","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1016\/j.immuni.2020.10.001","volume":"53","author":"C Perner","year":"2020","unstructured":"Perner C et al (2020) Substance P release by sensory neurons triggers dendritic cell migration and initiates the Type-2 immune response to allergens. Immunity 53:1063\u20131077e1067. https:\/\/doi.org\/10.1016\/j.immuni.2020.10.001","journal-title":"Immunity"},{"key":"9115_CR34","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1038\/s41590-019-0493-z","volume":"20","author":"N Serhan","year":"2019","unstructured":"Serhan N et al (2019) House dust mites activate nociceptor-mast cell clusters to drive type 2 skin inflammation. Nat Immunol 20:1435\u20131443. https:\/\/doi.org\/10.1038\/s41590-019-0493-z","journal-title":"Nat Immunol"},{"key":"9115_CR35","doi-asserted-by":"publisher","first-page":"2510","DOI":"10.1002\/med.22048","volume":"44","author":"VK Boda","year":"2024","unstructured":"Boda VK, Yasmen N, Jiang J, Li W (2024) Pathophysiological significance and modulation of the transient receptor potential canonical 3 ion channel. Med Res Rev 44:2510\u20132544. https:\/\/doi.org\/10.1002\/med.22048","journal-title":"Med Res Rev"},{"key":"9115_CR36","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24108601","author":"AP Kalinovskii","year":"2023","unstructured":"Kalinovskii AP, Utkina LL, Korolkova YV, Andreev YA (2023) TRPV3 ion channel: from gene to pharmacology. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms24108601","journal-title":"Int J Mol Sci"},{"key":"9115_CR37","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.jaci.2016.12.980","volume":"140","author":"E Azimi","year":"2017","unstructured":"Azimi E et al (2017) Substance P activates Mas-related G protein-coupled receptors to induce itch. J Allergy Clin Immunol 140:447\u2013453e443. https:\/\/doi.org\/10.1016\/j.jaci.2016.12.980","journal-title":"J Allergy Clin Immunol"},{"key":"9115_CR38","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/j.neuron.2019.01.012","volume":"101","author":"DP Green","year":"2019","unstructured":"Green DP, Limjunyawong N, Gour N, Pundir P, Dong X (2019) A mast-cell-specific receptor mediates neurogenic inflammation and pain. Neuron 101:412-420.e413. https:\/\/doi.org\/10.1016\/j.neuron.2019.01.012","journal-title":"Neuron"},{"key":"9115_CR39","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/j.immuni.2019.03.013","volume":"50","author":"J Meixiong","year":"2019","unstructured":"Meixiong J et al (2019) Activation of Mast-Cell-Expressed Mas-Related G-Protein-Coupled receptors drives Non-histaminergic itch. Immunity 50:1163\u20131171e1165. https:\/\/doi.org\/10.1016\/j.immuni.2019.03.013","journal-title":"Immunity"},{"key":"9115_CR40","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.jdermsci.2019.07.007","volume":"95","author":"B Peng","year":"2019","unstructured":"Peng B et al (2019) Thimerosal induces skin pseudo-allergic reaction via Mas-related G-protein coupled receptor B2. J Dermatol Sci 95:99\u2013106. https:\/\/doi.org\/10.1016\/j.jdermsci.2019.07.007","journal-title":"J Dermatol Sci"},{"key":"9115_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellimm.2019.103923","volume":"341","author":"Y Zeng","year":"2019","unstructured":"Zeng Y et al (2019) Gold induces a pseudo-allergic reaction via MRGPRX2 both in vitro and in vivo. Cell Immunol 341:103923. https:\/\/doi.org\/10.1016\/j.cellimm.2019.103923","journal-title":"Cell Immunol"},{"key":"9115_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2020.106258","volume":"81","author":"Y Hao","year":"2020","unstructured":"Hao Y et al (2020) Imiquimod-related dermatitis is mainly mediated by mast cell degranulation via Mas-related G-protein coupled receptor B2. Int Immunopharmacol 81:106258. https:\/\/doi.org\/10.1016\/j.intimp.2020.106258","journal-title":"Int Immunopharmacol"},{"key":"9115_CR43","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.jaci.2021.12.794","volume":"150","author":"M Bandyopadhyay","year":"2022","unstructured":"Bandyopadhyay M et al (2022) Skin codelivery of contact sensitizers and neurokinin-1 receptor antagonists integrated in microneedle arrays suppresses allergic contact dermatitis. J Allergy Clin Immunol 150:114\u2013130. https:\/\/doi.org\/10.1016\/j.jaci.2021.12.794","journal-title":"J Allergy Clin Immunol"},{"key":"9115_CR44","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1016\/j.jaci.2014.05.004","volume":"134","author":"D Fujisawa","year":"2014","unstructured":"Fujisawa D et al (2014) Expression of Mas-related gene X2 on mast cells is upregulated in the skin of patients with severe chronic urticaria. J Allergy Clin Immunol 134:622\u2013633e629. https:\/\/doi.org\/10.1016\/j.jaci.2014.05.004","journal-title":"J Allergy Clin Immunol"},{"key":"9115_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbih.2021.100361","volume":"18","author":"YJ Kim","year":"2021","unstructured":"Kim YJ, Granstein RD (2021) Roles of calcitonin gene-related peptide in the skin, and other physiological and pathophysiological functions. Brain, Behavior, & Immunity - Health 18:100361. https:\/\/doi.org\/10.1016\/j.bbih.2021.100361","journal-title":"Brain, Behavior, & Immunity - Health"},{"key":"9115_CR46","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1152\/physrev.00034.2013","volume":"94","author":"FA Russell","year":"2014","unstructured":"Russell FA, King R, Smillie SJ, Kodji X, Brain SD (2014) Calcitonin gene-related peptide: physiology and pathophysiology. Physiol Rev 94:1099\u20131142. https:\/\/doi.org\/10.1152\/physrev.00034.2013","journal-title":"Physiol Rev"},{"key":"9115_CR47","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1111\/j.1365-2133.2009.09318.x","volume":"161","author":"C Ant\u00fanez","year":"2009","unstructured":"Ant\u00fanez C et al (2009) Calcitonin gene-related peptide modulates interleukin-13 in circulating cutaneous lymphocyte-associated antigen-positive T cells in patients with atopic dermatitis. Br J Dermatol 161:547\u2013553. https:\/\/doi.org\/10.1111\/j.1365-2133.2009.09318.x","journal-title":"Br J Dermatol"},{"key":"9115_CR48","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1016\/j.jaci.2020.09.028","volume":"147","author":"C Larkin","year":"2021","unstructured":"Larkin C et al (2021) Novel insights into the TRPV3-mediated itch in atopic dermatitis. J Allergy Clin Immunol 147:1110\u20131114e1115. https:\/\/doi.org\/10.1016\/j.jaci.2020.09.028","journal-title":"J Allergy Clin Immunol"},{"key":"9115_CR49","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1007\/s10741-021-10105-w","volume":"27","author":"V Castiglione","year":"2022","unstructured":"Castiglione V et al (2022) Biomarkers for the diagnosis and management of heart failure. Heart Fail Rev 27:625\u2013643. https:\/\/doi.org\/10.1007\/s10741-021-10105-w","journal-title":"Heart Fail Rev"},{"key":"9115_CR50","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abe3037","volume":"13","author":"PY Tseng","year":"2021","unstructured":"Tseng PY, Hoon MA (2021) Oncostatin M can sensitize sensory neurons in inflammatory pruritus. Sci Transl Med 13:eabe3037. https:\/\/doi.org\/10.1126\/scitranslmed.abe3037","journal-title":"Sci Transl Med"},{"key":"9115_CR51","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1571120","volume":"16","author":"C Ishikawa","year":"2025","unstructured":"Ishikawa C et al (2025) Oncostatin M enhances the lengthening of sensory nerves and skin hypersensitivity. Front Immunol 16:1571120. https:\/\/doi.org\/10.3389\/fimmu.2025.1571120","journal-title":"Front Immunol"},{"key":"9115_CR52","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.tips.2023.02.002","volume":"44","author":"C Cao","year":"2023","unstructured":"Cao C, Roth BL (2023) The structure, function, and pharmacology of MRGPRs. Trends Pharmacol Sci 44:237\u2013251. https:\/\/doi.org\/10.1016\/j.tips.2023.02.002","journal-title":"Trends Pharmacol Sci"},{"key":"9115_CR53","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.immuni.2023.12.012","volume":"57","author":"N Gour","year":"2024","unstructured":"Gour N, Dong X (2024) The MRGPR family of receptors in immunity. Immunity 57:28\u201339. https:\/\/doi.org\/10.1016\/j.immuni.2023.12.012","journal-title":"Immunity"},{"key":"9115_CR54","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1016\/j.cell.2009.11.034","volume":"139","author":"Q Liu","year":"2009","unstructured":"Liu Q et al (2009) Sensory neuron-specific GPCR Mrgprs are itch receptors mediating chloroquine-induced pruritus. Cell 139:1353\u20131365. https:\/\/doi.org\/10.1016\/j.cell.2009.11.034","journal-title":"Cell"},{"key":"9115_CR55","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/nature14022","volume":"519","author":"BD McNeil","year":"2015","unstructured":"McNeil BD et al (2015) Identification of a mast-cell-specific receptor crucial for pseudo-allergic drug reactions. Nature 519:237\u2013241. https:\/\/doi.org\/10.1038\/nature14022","journal-title":"Nature"},{"key":"9115_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2022.108259","volume":"238","author":"G Al Hamwi","year":"2022","unstructured":"Al Hamwi G et al (2022) MAS-related G protein-coupled receptors X (MRGPRX): orphan GPCRs with potential as targets for future drugs. Pharmacol Ther 238:108259. https:\/\/doi.org\/10.1016\/j.pharmthera.2022.108259","journal-title":"Pharmacol Ther"},{"key":"9115_CR57","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/112_2020_53","volume":"179","author":"YN Mi","year":"2021","unstructured":"Mi YN, Ping NN, Cao YX (2021) Ligands and signaling of Mas-Related G Protein-Coupled Receptor-X2 in mast cell activation. Rev Physiol Biochem Pharmacol 179:139\u2013188. https:\/\/doi.org\/10.1007\/112_2020_53","journal-title":"Rev Physiol Biochem Pharmacol"},{"key":"9115_CR58","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1093\/brain\/awu007","volume":"137","author":"L Qu","year":"2014","unstructured":"Qu L et al (2014) Enhanced excitability of MRGPRA3- and MRGPRD-positive nociceptors in a model of inflammatory itch and pain. Brain 137:1039\u20131050. https:\/\/doi.org\/10.1093\/brain\/awu007","journal-title":"Brain"},{"key":"9115_CR59","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1016\/j.cell.2021.03.002","volume":"184","author":"S Zhang","year":"2021","unstructured":"Zhang S et al (2021) Nonpeptidergic neurons suppress mast cells via glutamate to maintain skin homeostasis. Cell 184:2151\u20132166e2116. https:\/\/doi.org\/10.1016\/j.cell.2021.03.002","journal-title":"Cell"},{"key":"9115_CR60","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1016\/j.jid.2021.08.433","volume":"142","author":"K Beattie","year":"2022","unstructured":"Beattie K et al (2022) TRPC3 antagonizes pruritus in a mouse contact dermatitis model. J Invest Dermatol 142:1136\u20131144. https:\/\/doi.org\/10.1016\/j.jid.2021.08.433","journal-title":"J Invest Dermatol"},{"key":"9115_CR61","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s11658-022-00316-w","volume":"27","author":"B Liu","year":"2022","unstructured":"Liu B et al (2022) Exploring neuronal mechanisms involved in the scratching behavior of a mouse model of allergic contact dermatitis by transcriptomics. Cell Mol Biol Lett 27:16. https:\/\/doi.org\/10.1186\/s11658-022-00316-w","journal-title":"Cell Mol Biol Lett"},{"key":"9115_CR62","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22084130","author":"J Sroka-Tomaszewska","year":"2021","unstructured":"Sroka-Tomaszewska J, Trzeciak M (2021) Molecular mechanisms of atopic dermatitis pathogenesis. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms22084130","journal-title":"Int J Mol Sci"},{"key":"9115_CR63","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1016\/j.jid.2023.10.019","volume":"144","author":"CFt Schuler","year":"2024","unstructured":"Schuler CFt et al (2024) Genetic and immunological pathogenesis of atopic dermatitis. J Invest Dermatol 144:954\u2013968. https:\/\/doi.org\/10.1016\/j.jid.2023.10.019","journal-title":"J Invest Dermatol"},{"key":"9115_CR64","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.alit.2021.11.001","volume":"71","author":"LF Koh","year":"2022","unstructured":"Koh LF, Ong RY, Common JE (2022) Skin microbiome of atopic dermatitis. Allergol Int 71:31\u201339. https:\/\/doi.org\/10.1016\/j.alit.2021.11.001","journal-title":"Allergol Int"},{"key":"9115_CR65","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1038\/s41423-023-00992-4","volume":"20","author":"P Facheris","year":"2023","unstructured":"Facheris P, Jeffery J, Del Duca E, Guttman-Yassky E (2023) The translational revolution in atopic dermatitis: the paradigm shift from pathogenesis to treatment. Cell Mol Immunol 20:448\u2013474. https:\/\/doi.org\/10.1038\/s41423-023-00992-4","journal-title":"Cell Mol Immunol"},{"key":"9115_CR66","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1046\/j.1365-2222.2001.01176.x","volume":"31","author":"VH van der Velden","year":"2001","unstructured":"van der Velden VH et al (2001) Selective development of a strong Th2 cytokine profile in high-risk children who develop atopy: risk factors and regulatory role of IFN-gamma, IL-4 and IL-10. Clin Experimental Allergy: J Br Soc Allergy Clin Immunol 31:997\u20131006. https:\/\/doi.org\/10.1046\/j.1365-2222.2001.01176.x","journal-title":"Clin Experimental Allergy: J Br Soc Allergy Clin Immunol"},{"key":"9115_CR67","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1016\/j.jaci.2018.02.040","volume":"141","author":"PM Brunner","year":"2018","unstructured":"Brunner PM et al (2018) Early-onset pediatric atopic dermatitis is characterized by T(H)2\/T(H)17\/T(H)22-centered inflammation and lipid alterations. J Allergy Clin Immunol 141:2094\u20132106. https:\/\/doi.org\/10.1016\/j.jaci.2018.02.040","journal-title":"J Allergy Clin Immunol"},{"key":"9115_CR68","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.jaci.2019.01.015","volume":"144","author":"L Zhou","year":"2019","unstructured":"Zhou L et al (2019) Age-specific changes in the molecular phenotype of patients with moderate-to-severe atopic dermatitis. J Allergy Clin Immunol 144:144\u2013156. https:\/\/doi.org\/10.1016\/j.jaci.2019.01.015","journal-title":"J Allergy Clin Immunol"},{"key":"9115_CR69","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1016\/j.jaci.2012.07.012","volume":"130","author":"JK Gittler","year":"2012","unstructured":"Gittler JK et al (2012) Progressive activation of T(H)2\/T(H)22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis. J Allergy Clin Immunol 130:1344\u20131354. https:\/\/doi.org\/10.1016\/j.jaci.2012.07.012","journal-title":"J Allergy Clin Immunol"},{"key":"9115_CR70","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaci.2018.10.032","volume":"143","author":"T Czarnowicki","year":"2019","unstructured":"Czarnowicki T, He H, Krueger JG, Guttman-Yassky E (2019) Atopic dermatitis endotypes and implications for targeted therapeutics. J Allergy Clin Immunol 143:1\u201311. https:\/\/doi.org\/10.1016\/j.jaci.2018.10.032","journal-title":"J Allergy Clin Immunol"},{"key":"9115_CR71","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1111\/exd.12967","volume":"25","author":"BC Martel","year":"2016","unstructured":"Martel BC et al (2016) Distinct molecular signatures of mild extrinsic and intrinsic atopic dermatitis. Exp Dermatol 25:453\u2013459. https:\/\/doi.org\/10.1111\/exd.12967","journal-title":"Exp Dermatol"},{"key":"9115_CR72","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.jdermsci.2012.04.004","volume":"67","author":"R Kabashima-Kubo","year":"2012","unstructured":"Kabashima-Kubo R et al (2012) A group of atopic dermatitis without IgE elevation or barrier impairment shows a high Th1 frequency: possible immunological state of the intrinsic type. J Dermatol Sci 67:37\u201343. https:\/\/doi.org\/10.1016\/j.jdermsci.2012.04.004","journal-title":"J Dermatol Sci"},{"key":"9115_CR73","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/j.ajpath.2012.11.039","volume":"182","author":"CS Moniaga","year":"2013","unstructured":"Moniaga CS et al (2013) Protease activity enhances production of thymic stromal lymphopoietin and basophil accumulation in flaky tail mice. Am J Pathol 182:841\u2013851. https:\/\/doi.org\/10.1016\/j.ajpath.2012.11.039","journal-title":"Am J Pathol"},{"key":"9115_CR74","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19103086","author":"J Klonowska","year":"2018","unstructured":"Klonowska J, Gle\u0144 J, Nowicki RJ, Trzeciak M (2018) New cytokines in the pathogenesis of atopic dermatitis\u2014new therapeutic targets. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms19103086","journal-title":"Int J Mol Sci"},{"key":"9115_CR75","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.jaci.2020.12.628","volume":"148","author":"J Borowczyk","year":"2021","unstructured":"Borowczyk J, Shutova M, Brembilla NC, Boehncke WH (2021) IL-25 (IL-17E) in epithelial immunology and pathophysiology. J Allergy Clin Immunol 148:40\u201352. https:\/\/doi.org\/10.1016\/j.jaci.2020.12.628","journal-title":"J Allergy Clin Immunol"},{"key":"9115_CR76","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1016\/j.jaci.2022.10.023","volume":"151","author":"CFt Schuler","year":"2023","unstructured":"Schuler CFt, Billi AC, Maverakis E, Tsoi LC, Gudjonsson JE (2023) Novel insights into atopic dermatitis. J Allergy Clin Immunol 151:1145\u20131154. https:\/\/doi.org\/10.1016\/j.jaci.2022.10.023","journal-title":"J Allergy Clin Immunol"},{"key":"9115_CR77","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10091976","author":"CH Bang","year":"2021","unstructured":"Bang CH et al (2021) Production of IL-31 in CD45RO(+)CLA(+)H4R(+) T cells in atopic dermatitis. J Clin Med. https:\/\/doi.org\/10.3390\/jcm10091976","journal-title":"J Clin Med"},{"key":"9115_CR78","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.alit.2021.01.005","volume":"70","author":"S Imamura","year":"2021","unstructured":"Imamura S et al (2021) Activated steady status and distinctive Fc\u03b5RI-mediated responsiveness in basophils of atopic dermatitis. Allergol Int 70:327\u2013334. https:\/\/doi.org\/10.1016\/j.alit.2021.01.005","journal-title":"Allergol Int"},{"key":"9115_CR79","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/j.jaci.2022.11.009","volume":"151","author":"T Hashimoto","year":"2023","unstructured":"Hashimoto T, Yokozeki H, Karasuyama H, Satoh T (2023) IL-31-generating network in atopic dermatitis comprising macrophages, basophils, thymic stromal lymphopoietin, and periostin. J Allergy Clin Immunol 151:737-746.e736. https:\/\/doi.org\/10.1016\/j.jaci.2022.11.009","journal-title":"J Allergy Clin Immunol"},{"key":"9115_CR80","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2020.03.036","volume":"31","author":"SK Mishra","year":"2020","unstructured":"Mishra SK et al (2020) Periostin activation of integrin receptors on sensory neurons induces allergic itch. Cell Rep 31:107472. https:\/\/doi.org\/10.1016\/j.celrep.2020.03.036","journal-title":"Cell Rep"},{"key":"9115_CR81","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1593141","volume":"16","author":"D Horv\u00e1th","year":"2025","unstructured":"Horv\u00e1th D et al (2025) Natriuretic peptides modulate monocyte-derived Langerhans cell differentiation and promote a migratory phenotype. Front Immunol 16:1593141. https:\/\/doi.org\/10.3389\/fimmu.2025.1593141","journal-title":"Front Immunol"},{"key":"9115_CR82","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.immuni.2020.06.023","volume":"53","author":"J Xu","year":"2020","unstructured":"Xu J et al (2020) The cytokine TGF-\u03b2 induces Interleukin-31 expression from dermal dendritic cells to activate sensory neurons and stimulate wound itching. Immunity 53:371\u2013383e375. https:\/\/doi.org\/10.1016\/j.immuni.2020.06.023","journal-title":"Immunity"},{"key":"9115_CR83","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1016\/j.cell.2018.04.006","volume":"173","author":"FA Pinho-Ribeiro","year":"2018","unstructured":"Pinho-Ribeiro FA et al (2018) Blocking neuronal signaling to immune cells treats Streptococcal invasive infection. Cell 173:1083\u20131097e1022. https:\/\/doi.org\/10.1016\/j.cell.2018.04.006","journal-title":"Cell"},{"key":"9115_CR84","doi-asserted-by":"publisher","first-page":"5371","DOI":"10.4049\/jimmunol.1300300","volume":"191","author":"MH Oh","year":"2013","unstructured":"Oh MH et al (2013) TRPA1-dependent pruritus in IL-13-induced chronic atopic dermatitis. J Immunol 191:5371\u20135382. https:\/\/doi.org\/10.4049\/jimmunol.1300300","journal-title":"J Immunol"},{"key":"9115_CR85","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.cell.2013.08.057","volume":"155","author":"SR Wilson","year":"2013","unstructured":"Wilson SR et al (2013) The epithelial cell-derived atopic dermatitis cytokine TSLP activates neurons to induce itch. Cell 155:285\u2013295. https:\/\/doi.org\/10.1016\/j.cell.2013.08.057","journal-title":"Cell"},{"key":"9115_CR86","doi-asserted-by":"publisher","first-page":"2543","DOI":"10.4049\/jimmunol.1600126","volume":"198","author":"H Lou","year":"2017","unstructured":"Lou H et al (2017) Expression of IL-22 in the skin causes Th2-biased immunity, epidermal barrier dysfunction, and pruritus via stimulating epithelial Th2 cytokines and the GRP pathway. J Immunol 198:2543\u20132555. https:\/\/doi.org\/10.4049\/jimmunol.1600126","journal-title":"J Immunol"},{"key":"9115_CR87","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1016\/j.jid.2024.01.025","volume":"144","author":"Y Li","year":"2024","unstructured":"Li Y et al (2024) Neuronal BST2: A pruritic mediator alongside Protease-Activated receptor 2 in the IL-27-Driven itch pathway. J Invest Dermatol 144:1829\u20131842e1824. https:\/\/doi.org\/10.1016\/j.jid.2024.01.025","journal-title":"J Invest Dermatol"},{"key":"9115_CR88","doi-asserted-by":"publisher","DOI":"10.1016\/j.ynpai.2019.100032","volume":"6","author":"K Chung","year":"2019","unstructured":"Chung K et al (2019) Cathepsin S acts via protease-activated receptor 2 to activate sensory neurons and induce itch-like behaviour. Neurobiol Pain 6:100032. https:\/\/doi.org\/10.1016\/j.ynpai.2019.100032","journal-title":"Neurobiol Pain"},{"key":"9115_CR89","doi-asserted-by":"publisher","first-page":"2563","DOI":"10.2353\/ajpath.2010.090941","volume":"177","author":"S Seeliger","year":"2010","unstructured":"Seeliger S et al (2010) Pituitary adenylate cyclase activating polypeptide: an important vascular regulator in human skin in vivo. Am J Pathol 177:2563\u20132575. https:\/\/doi.org\/10.2353\/ajpath.2010.090941","journal-title":"Am J Pathol"},{"key":"9115_CR90","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1016\/j.jid.2023.07.029","volume":"144","author":"JW Ahn","year":"2024","unstructured":"Ahn JW et al (2024) Cav3.2 T-Type calcium channel mediates acute itch and contributes to chronic itch and inflammation in experimental atopic dermatitis. J Invest Dermatol 144:612\u2013620e616. https:\/\/doi.org\/10.1016\/j.jid.2023.07.029","journal-title":"J Invest Dermatol"},{"key":"9115_CR91","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/s004280050179","volume":"432","author":"R Urashima","year":"1998","unstructured":"Urashima R, Mihara M (1998) Cutaneous nerves in atopic dermatitis. A histological, immunohistochemical and electron microscopic study. Virchows Arch 432:363\u2013370. https:\/\/doi.org\/10.1007\/s004280050179","journal-title":"Virchows Arch"},{"key":"9115_CR92","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s00403-006-0657-1","volume":"298","author":"YC Dou","year":"2006","unstructured":"Dou YC, Hagstr\u00f6mer L, Emtestam L, Johansson O (2006) Increased nerve growth factor and its receptors in atopic dermatitis: an immunohistochemical study. Arch Dermatol Res 298:31\u201337. https:\/\/doi.org\/10.1007\/s00403-006-0657-1","journal-title":"Arch Dermatol Res"},{"key":"9115_CR93","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1111\/j.1365-2133.2007.08410.x","volume":"158","author":"M Tominaga","year":"2008","unstructured":"Tominaga M, Ogawa H, Takamori K (2008) Decreased production of semaphorin 3A in the lesional skin of atopic dermatitis. Br J Dermatol 158:842\u2013844. https:\/\/doi.org\/10.1111\/j.1365-2133.2007.08410.x","journal-title":"Br J Dermatol"},{"key":"9115_CR94","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1111\/j.1365-2133.2006.07636.x","volume":"156","author":"N Takano","year":"2007","unstructured":"Takano N, Sakurai T, Ohashi Y, Kurachi M (2007) Effects of high-affinity nerve growth factor receptor inhibitors on symptoms in the NC\/Nga mouse atopic dermatitis model. Br J Dermatol 156:241\u2013246. https:\/\/doi.org\/10.1111\/j.1365-2133.2006.07636.x","journal-title":"Br J Dermatol"},{"key":"9115_CR95","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.jdermsci.2014.06.005","volume":"76","author":"T Sakai","year":"2014","unstructured":"Sakai T et al (2014) Co-stimulation with interleukin-4 and tumor necrosis factor-\u03b1 increases epidermal innervation accompanied by suppression of semaphorin 3A. J Dermatol Sci 76:69\u201371. https:\/\/doi.org\/10.1016\/j.jdermsci.2014.06.005","journal-title":"J Dermatol Sci"},{"key":"9115_CR96","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/j.jaci.2016.02.020","volume":"138","author":"M Feld","year":"2016","unstructured":"Feld M et al (2016) The pruritus- and TH2-associated cytokine IL-31 promotes growth of sensory nerves. J Allergy Clin Immunol 138:500\u2013508e524. https:\/\/doi.org\/10.1016\/j.jaci.2016.02.020","journal-title":"J Allergy Clin Immunol"},{"key":"9115_CR97","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1016\/j.jaci.2005.02.007","volume":"115","author":"U Raap","year":"2005","unstructured":"Raap U et al (2005) Brain-derived neurotrophic factor is increased in atopic dermatitis and modulates eosinophil functions compared with that seen in nonatopic subjects. J Allergy Clin Immunol 115:1268\u20131275. https:\/\/doi.org\/10.1016\/j.jaci.2005.02.007","journal-title":"J Allergy Clin Immunol"},{"key":"9115_CR98","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0022029","volume":"6","author":"EL Foster","year":"2011","unstructured":"Foster EL et al (2011) Eosinophils increase neuron branching in human and murine skin and in vitro. PLoS One 6:e22029. https:\/\/doi.org\/10.1371\/journal.pone.0022029","journal-title":"PLoS One"},{"key":"9115_CR99","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1111\/cea.13560","volume":"50","author":"D Guseva","year":"2020","unstructured":"Guseva D et al (2020) Neuronal branching of sensory neurons is associated with BDNF-positive eosinophils in atopic dermatitis. Clin Exp Allergy 50:577\u2013584. https:\/\/doi.org\/10.1111\/cea.13560","journal-title":"Clin Exp Allergy"},{"key":"9115_CR100","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/j.jaci.2012.05.027","volume":"130","author":"H Murota","year":"2012","unstructured":"Murota H et al (2012) Artemin causes hypersensitivity to warm sensation, mimicking warmth-provoked pruritus in atopic dermatitis. J Allergy Clin Immunol 130:671\u2013682e674. https:\/\/doi.org\/10.1016\/j.jaci.2012.05.027","journal-title":"J Allergy Clin Immunol"},{"key":"9115_CR101","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1016\/j.jid.2024.01.017","volume":"144","author":"H Yeo","year":"2024","unstructured":"Yeo H et al (2024) The EGR1-Artemin axis in keratinocytes enhances the innervation of epidermal sensory neurons during skin inflammation induced by house dust mite extract from dermatophagoidesfarinae. J Invest Dermatol 144:1817\u20131828e1817. https:\/\/doi.org\/10.1016\/j.jid.2024.01.017","journal-title":"J Invest Dermatol"},{"key":"9115_CR102","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.jdermsci.2010.02.010","volume":"58","author":"S Tengara","year":"2010","unstructured":"Tengara S et al (2010) Keratinocyte-derived anosmin-1, an extracellular glycoprotein encoded by the X-linked Kallmann syndrome gene, is involved in modulation of epidermal nerve density in atopic dermatitis. J Dermatol Sci 58:64\u201371. https:\/\/doi.org\/10.1016\/j.jdermsci.2010.02.010","journal-title":"J Dermatol Sci"},{"key":"9115_CR103","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1038\/labinvest.2010.193","volume":"91","author":"Y Hashimoto","year":"2011","unstructured":"Hashimoto Y et al (2011) CFTR-deficiency renders mice highly susceptible to cutaneous symptoms during mite infestation. Lab Invest 91:509\u2013518. https:\/\/doi.org\/10.1038\/labinvest.2010.193","journal-title":"Lab Invest"},{"key":"9115_CR104","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1016\/j.ajpath.2019.05.017","volume":"189","author":"T Andoh","year":"2019","unstructured":"Andoh T et al (2019) Involvement of \u03b1-melanocyte-stimulating hormone-thromboxane A(2) system on itching in atopic dermatitis. Am J Pathol 189:1775\u20131785. https:\/\/doi.org\/10.1016\/j.ajpath.2019.05.017","journal-title":"Am J Pathol"},{"key":"9115_CR105","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1111\/bph.15733","volume":"179","author":"B Sanjel","year":"2022","unstructured":"Sanjel B, Kim BH, Song MH, Carstens E, Shim WS (2022) Glucosylsphingosine evokes pruritus via activation of 5-HT(2A) receptor and TRPV4 in sensory neurons. Br J Pharmacol 179:2193\u20132207. https:\/\/doi.org\/10.1111\/bph.15733","journal-title":"Br J Pharmacol"},{"key":"9115_CR106","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2025.116952","volume":"237","author":"DE Song","year":"2025","unstructured":"Song DE, Rawal D, Lee WJ, Shim WS (2025) Sphingosylphosphorylcholine induces itch via activation of TRPM3 and TRPA1 in mice. Biochem Pharmacol 237:116952. https:\/\/doi.org\/10.1016\/j.bcp.2025.116952","journal-title":"Biochem Pharmacol"},{"key":"9115_CR107","doi-asserted-by":"publisher","DOI":"10.3389\/fnmol.2023.1086285","volume":"16","author":"GK Zhou","year":"2023","unstructured":"Zhou GK et al (2023) Acid-sensing ion channel 3 is required for agmatine-induced histamine-independent itch in mice. Front Mol Neurosci 16:1086285. https:\/\/doi.org\/10.3389\/fnmol.2023.1086285","journal-title":"Front Mol Neurosci"},{"key":"9115_CR108","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/j.jid.2021.07.178","volume":"142","author":"PY Tseng","year":"2022","unstructured":"Tseng PY, Hoon MA (2022) Specific \u03b2-defensins stimulate pruritus through activation of sensory neurons. J Invest Dermatol 142:594\u2013602. https:\/\/doi.org\/10.1016\/j.jid.2021.07.178","journal-title":"J Invest Dermatol"},{"key":"9115_CR109","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2022087118","author":"T Voisin","year":"2021","unstructured":"Voisin T et al (2021) The CysLT(2)R receptor mediates leukotriene C(4)-driven acute and chronic itch. Proc Natl Acad Sci U S A. https:\/\/doi.org\/10.1073\/pnas.2022087118","journal-title":"Proc Natl Acad Sci U S A"},{"key":"9115_CR110","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.cell.2020.12.033","volume":"184","author":"F Wang","year":"2021","unstructured":"Wang F et al (2021) A basophil-neuronal axis promotes itch. Cell 184:422\u2013440e417. https:\/\/doi.org\/10.1016\/j.cell.2020.12.033","journal-title":"Cell"},{"key":"9115_CR111","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1038\/jid.2012.464","volume":"133","author":"D Roggenkamp","year":"2013","unstructured":"Roggenkamp D et al (2013) Epidermal nerve fibers modulate keratinocyte growth via neuropeptide signaling in an innervated skin model. J Invest Dermatol 133:1620\u20131628. https:\/\/doi.org\/10.1038\/jid.2012.464","journal-title":"J Invest Dermatol"},{"key":"9115_CR112","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.jdermsci.2015.02.021","volume":"78","author":"S Matsumura","year":"2015","unstructured":"Matsumura S, Terao M, Murota H, Katayama I (2015) Th2 cytokines enhance TrkA expression, upregulate proliferation, and downregulate differentiation of keratinocytes. J Dermatol Sci 78:215\u2013223. https:\/\/doi.org\/10.1016\/j.jdermsci.2015.02.021","journal-title":"J Dermatol Sci"},{"key":"9115_CR113","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s12016-021-08875-0","volume":"61","author":"Y Li","year":"2021","unstructured":"Li Y, Li L (2021) Contact dermatitis: classifications and management. Clin Rev Allergy Immunol 61:245\u2013281. https:\/\/doi.org\/10.1007\/s12016-021-08875-0","journal-title":"Clin Rev Allergy Immunol"},{"key":"9115_CR114","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-021-00271-4","volume":"7","author":"PL Scheinman","year":"2021","unstructured":"Scheinman PL et al (2021) Contact dermatitis. Nat Rev Dis Primers 7:38. https:\/\/doi.org\/10.1038\/s41572-021-00271-4","journal-title":"Nat Rev Dis Primers"},{"key":"9115_CR115","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1016\/j.jaci.2022.02.002","volume":"149","author":"JD Johansen","year":"2022","unstructured":"Johansen JD, Bonefeld CM, Schwensen JFB, Thyssen JP, Uter W (2022) Novel insights into contact dermatitis. J Allergy Clin Immunol 149:1162\u20131171. https:\/\/doi.org\/10.1016\/j.jaci.2022.02.002","journal-title":"J Allergy Clin Immunol"},{"key":"9115_CR116","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1184289","volume":"10","author":"M Tramontana","year":"2023","unstructured":"Tramontana M et al (2023) Advancing the understanding of allergic contact dermatitis: from pathophysiology to novel therapeutic approaches. Front Med (Lausanne) 10:1184289. https:\/\/doi.org\/10.3389\/fmed.2023.1184289","journal-title":"Front Med (Lausanne)"},{"key":"9115_CR117","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241612975","author":"HL Yamaguchi","year":"2023","unstructured":"Yamaguchi HL, Yamaguchi Y, Peeva E (2023) Role of innate immunity in allergic contact dermatitis: an update. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms241612975","journal-title":"Int J Mol Sci"},{"key":"9115_CR118","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.124497","author":"B Liu","year":"2019","unstructured":"Liu B et al (2019) Transcriptome profiling reveals Th2 bias and identifies endogenous itch mediators in poison ivy contact dermatitis. JCI Insight. https:\/\/doi.org\/10.1172\/jci.insight.124497","journal-title":"JCI Insight"},{"key":"9115_CR119","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s12016-018-8713-0","volume":"56","author":"SN Bains","year":"2019","unstructured":"Bains SN, Nash P, Fonacier L (2019) Irritant contact dermatitis. Clin Rev Allergy Immunol 56:99\u2013109. https:\/\/doi.org\/10.1007\/s12016-018-8713-0","journal-title":"Clin Rev Allergy Immunol"},{"key":"9115_CR120","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s13671-021-00351-4","volume":"11","author":"K Patel","year":"2022","unstructured":"Patel K, Nixon R (2022) Irritant contact dermatitis - a review. Curr Dermatol Rep 11:41\u201351. https:\/\/doi.org\/10.1007\/s13671-021-00351-4","journal-title":"Curr Dermatol Rep"},{"key":"9115_CR121","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.jneuroim.2005.08.012","volume":"169","author":"A B\u00e1nv\u00f6lgyi","year":"2005","unstructured":"B\u00e1nv\u00f6lgyi A et al (2005) Evidence for a novel protective role of the vanilloid TRPV1 receptor in a cutaneous contact allergic dermatitis model. J Neuroimmunol 169:86\u201396. https:\/\/doi.org\/10.1016\/j.jneuroim.2005.08.012","journal-title":"J Neuroimmunol"},{"key":"9115_CR122","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.jneuroim.2008.12.001","volume":"207","author":"T Shiba","year":"2009","unstructured":"Shiba T et al (2009) TRPA1 and TRPV1 activation is a novel adjuvant effect mechanism in contact hypersensitivity. J Neuroimmunol 207:66\u201374. https:\/\/doi.org\/10.1016\/j.jneuroim.2008.12.001","journal-title":"J Neuroimmunol"},{"key":"9115_CR123","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1016\/j.lfs.2011.03.017","volume":"88","author":"CR Silva","year":"2011","unstructured":"Silva CR et al (2011) The involvement of TRPA1 channel activation in the inflammatory response evoked by topical application of cinnamaldehyde to mice. Life Sci 88:1077\u20131087. https:\/\/doi.org\/10.1016\/j.lfs.2011.03.017","journal-title":"Life Sci"},{"key":"9115_CR124","doi-asserted-by":"publisher","first-page":"3549","DOI":"10.1096\/fj.13-229948","volume":"27","author":"B Liu","year":"2013","unstructured":"Liu B et al (2013) TRPA1 controls inflammation and pruritogen responses in allergic contact dermatitis. FASEB J 27:3549\u20133563. https:\/\/doi.org\/10.1096\/fj.13-229948","journal-title":"FASEB J"},{"key":"9115_CR125","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1096\/fj.03-0658fje","volume":"18","author":"TE Scholzen","year":"2004","unstructured":"Scholzen TE et al (2004) Cutaneous allergic contact dermatitis responses are diminished in mice deficient in neurokinin 1 receptors and augmented by neurokinin 2 receptor blockage. FASEB J 18:1007\u20131009. https:\/\/doi.org\/10.1096\/fj.03-0658fje","journal-title":"FASEB J"},{"key":"9115_CR126","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1606608113","volume":"113","author":"B Liu","year":"2016","unstructured":"Liu B et al (2016) IL-33\/ST2 signaling excites sensory neurons and mediates itch response in a mouse model of poison ivy contact allergy. Proc Natl Acad Sci USA 113:E7572-e7579. https:\/\/doi.org\/10.1073\/pnas.1606608113","journal-title":"Proc Natl Acad Sci USA"},{"key":"9115_CR127","doi-asserted-by":"publisher","first-page":"6886","DOI":"10.4049\/jimmunol.1100028","volume":"186","author":"N Mikami","year":"2011","unstructured":"Mikami N et al (2011) Calcitonin gene-related peptide is an important regulator of cutaneous immunity: effect on dendritic cell and T cell functions. J Immunol 186:6886\u20136893. https:\/\/doi.org\/10.4049\/jimmunol.1100028","journal-title":"J Immunol"},{"key":"9115_CR128","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.4049\/jimmunol.1500303","volume":"196","author":"W Ding","year":"2016","unstructured":"Ding W et al (2016) Calcitonin gene-related peptide-exposed endothelial cells bias antigen presentation to CD4\u2009+\u2009T cells toward a Th17 response. J Immunol 196:2181\u20132194. https:\/\/doi.org\/10.4049\/jimmunol.1500303","journal-title":"J Immunol"},{"key":"9115_CR129","doi-asserted-by":"publisher","first-page":"633","DOI":"10.4049\/jimmunol.2100139","volume":"208","author":"W Ding","year":"2022","unstructured":"Ding W et al (2022) Regulation of cutaneous immunity in vivo by calcitonin gene-related peptide signaling through endothelial cells. J Immunol 208:633\u2013641. https:\/\/doi.org\/10.4049\/jimmunol.2100139","journal-title":"J Immunol"},{"key":"9115_CR130","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1111\/j.1365-4632.2011.05197.x","volume":"51","author":"YY Lim","year":"2012","unstructured":"Lim YY et al (2012) A comparison of neuropeptide expression in skin with allergic contact dermatitis in human and mouse. Int J Dermatol 51:939\u2013946. https:\/\/doi.org\/10.1111\/j.1365-4632.2011.05197.x","journal-title":"Int J Dermatol"},{"key":"9115_CR131","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1016\/j.jaci.2021.02.005","volume":"148","author":"Y Yamamoto","year":"2021","unstructured":"Yamamoto Y et al (2021) Pituitary adenylate cyclase-activating polypeptide promotes cutaneous dendritic cell functions in contact hypersensitivity. J Allergy Clin Immunol 148:858\u2013866. https:\/\/doi.org\/10.1016\/j.jaci.2021.02.005","journal-title":"J Allergy Clin Immunol"},{"key":"9115_CR132","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1097\/j.pain.0000000000003540","volume":"166","author":"J Llim\u00f3s-Aubach","year":"2025","unstructured":"Llim\u00f3s-Aubach J et al (2025) TRESK background potassium channel regulates MrgprA3\u2009+\u2009pruriceptor excitability, acute and chronic itch. Pain 166:1796\u20131810. https:\/\/doi.org\/10.1097\/j.pain.0000000000003540","journal-title":"Pain"},{"key":"9115_CR133","doi-asserted-by":"publisher","first-page":"4769","DOI":"10.1172\/jci70528","volume":"123","author":"ZQ Zhao","year":"2013","unstructured":"Zhao ZQ et al (2013) Chronic itch development in sensory neurons requires BRAF signaling pathways. J Clin Invest 123:4769\u20134780. https:\/\/doi.org\/10.1172\/jci70528","journal-title":"J Clin Invest"},{"key":"9115_CR134","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1097\/j.pain.0000000000000208","volume":"156","author":"L Qu","year":"2015","unstructured":"Qu L, Fu K, Yang J, Shimada SG, LaMotte RH (2015) CXCR3 chemokine receptor signaling mediates itch in experimental allergic contact dermatitis. Pain 156:1737\u20131746. https:\/\/doi.org\/10.1097\/j.pain.0000000000000208","journal-title":"Pain"},{"key":"9115_CR135","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.bbi.2019.04.026","volume":"80","author":"H Jiang","year":"2019","unstructured":"Jiang H et al (2019) CCL2\/CCR2 signaling elicits itch- and pain-like behavior in a murine model of allergic contact dermatitis. Brain Behav Immun 80:464\u2013473. https:\/\/doi.org\/10.1016\/j.bbi.2019.04.026","journal-title":"Brain Behav Immun"},{"key":"9115_CR136","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1007\/s12016-017-8628-1","volume":"54","author":"S Radonjic-Hoesli","year":"2018","unstructured":"Radonjic-Hoesli S et al (2018) Urticaria and angioedema: an update on classification and pathogenesis. Clin Rev Allergy Immunol 54:88\u2013101. https:\/\/doi.org\/10.1007\/s12016-017-8628-1","journal-title":"Clin Rev Allergy Immunol"},{"key":"9115_CR137","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-022-00389-z","volume":"8","author":"P Kolkhir","year":"2022","unstructured":"Kolkhir P et al (2022) Urticaria. Nat Rev Dis Primers 8:61. https:\/\/doi.org\/10.1038\/s41572-022-00389-z","journal-title":"Nat Rev Dis Primers"},{"key":"9115_CR138","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1016\/j.jaci.2022.04.010","volume":"149","author":"P Kolkhir","year":"2022","unstructured":"Kolkhir P et al (2022) Autoimmune chronic spontaneous urticaria. J Allergy Clin Immunol 149:1819\u20131831. https:\/\/doi.org\/10.1016\/j.jaci.2022.04.010","journal-title":"J Allergy Clin Immunol"},{"key":"9115_CR139","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1111\/all.15603","volume":"78","author":"A Kaplan","year":"2023","unstructured":"Kaplan A et al (2023) Chronic spontaneous urticaria: focus on pathophysiology to unlock treatment advances. Allergy 78:389\u2013401. https:\/\/doi.org\/10.1111\/all.15603","journal-title":"Allergy"},{"key":"9115_CR140","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1001\/jama.2024.15568","volume":"332","author":"P Kolkhir","year":"2024","unstructured":"Kolkhir P, Bonnekoh H, Metz M, Maurer M (2024) Chronic spontaneous urticaria: a review. JAMA 332:1464\u20131477. https:\/\/doi.org\/10.1001\/jama.2024.15568","journal-title":"JAMA"},{"key":"9115_CR141","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1007\/s11882-024-01160-y","volume":"24","author":"M Mu\u00f1oz","year":"2024","unstructured":"Mu\u00f1oz M, Kiefer LA, Pereira MP, Bizjak M, Maurer M (2024) New insights into chronic inducible urticaria. Curr Allergy Asthma Rep 24:457\u2013469. https:\/\/doi.org\/10.1007\/s11882-024-01160-y","journal-title":"Curr Allergy Asthma Rep"},{"key":"9115_CR142","doi-asserted-by":"publisher","first-page":"2833","DOI":"10.1038\/jid.2014.226","volume":"134","author":"M Metz","year":"2014","unstructured":"Metz M et al (2014) Substance P is upregulated in the serum of patients with chronic spontaneous urticaria. J Invest Dermatol 134:2833\u20132836. https:\/\/doi.org\/10.1038\/jid.2014.226","journal-title":"J Invest Dermatol"},{"key":"9115_CR143","doi-asserted-by":"publisher","first-page":"498","DOI":"10.4168\/aair.2021.13.3.498","volume":"13","author":"TBT Cao","year":"2021","unstructured":"Cao TBT, Cha HY, Yang EM, Ye YM (2021) Elevated MRGPRX2 levels related to disease severity in patients with chronic spontaneous urticaria. Allergy Asthma Immunol Res 13:498\u2013506. https:\/\/doi.org\/10.4168\/aair.2021.13.3.498","journal-title":"Allergy Asthma Immunol Res"},{"key":"9115_CR144","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.alit.2021.05.002","volume":"70","author":"N Nishimori","year":"2021","unstructured":"Nishimori N et al (2021) Serum level of hemokinin-1 is significantly lower in patients with chronic spontaneous urticaria than in healthy subjects. Allergol Int 70:480\u2013488. https:\/\/doi.org\/10.1016\/j.alit.2021.05.002","journal-title":"Allergol Int"},{"key":"9115_CR145","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s10565-016-9330-4","volume":"32","author":"W Zheng","year":"2016","unstructured":"Zheng W, Wang J, Zhu W, Xu C, He S (2016) Upregulated expression of substance P in basophils of the patients with chronic spontaneous urticaria: induction of histamine release and basophil accumulation by substance P. Cell Biol Toxicol 32:217\u2013228. https:\/\/doi.org\/10.1007\/s10565-016-9330-4","journal-title":"Cell Biol Toxicol"},{"key":"9115_CR146","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1111\/cea.12348","volume":"44","author":"AB Kay","year":"2014","unstructured":"Kay AB et al (2014) Calcitonin gene-related peptide and vascular endothelial growth factor are expressed in lesional but not uninvolved skin in chronic spontaneous urticaria. Clin Exp Allergy 44:1053\u20131060. https:\/\/doi.org\/10.1111\/cea.12348","journal-title":"Clin Exp Allergy"},{"key":"9115_CR147","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/s41586-024-08002-x","volume":"635","author":"NH Gopee","year":"2024","unstructured":"Gopee NH et al (2024) A prenatal skin atlas reveals immune regulation of human skin morphogenesis. Nature 635:679\u2013689. https:\/\/doi.org\/10.1038\/s41586-024-08002-x","journal-title":"Nature"},{"key":"9115_CR148","doi-asserted-by":"publisher","DOI":"10.1177\/0963689720978219","volume":"30","author":"A Tenorio-Mina","year":"2021","unstructured":"Tenorio-Mina A et al (2021) Human keratinocytes adopt neuronal fates after in utero transplantation in the developing rat brain. Cell Transplant 30:963689720978219. https:\/\/doi.org\/10.1177\/0963689720978219","journal-title":"Cell Transplant"},{"key":"9115_CR149","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1111\/j.1600-0625.2006.00529.x","volume":"16","author":"M Denda","year":"2007","unstructured":"Denda M, Nakatani M, Ikeyama K, Tsutsumi M, Denda S (2007) Epidermal keratinocytes as the forefront of the sensory system. Exp Dermatol 16:157\u2013161. https:\/\/doi.org\/10.1111\/j.1600-0625.2006.00529.x","journal-title":"Exp Dermatol"},{"key":"9115_CR150","doi-asserted-by":"publisher","DOI":"10.3389\/fnbeh.2018.00127","volume":"12","author":"LD Godoy","year":"2018","unstructured":"Godoy LD, Rossignoli MT, Delfino-Pereira P, Garcia-Cairasco N, de Lima Umeoka EH (2018) A comprehensive overview on stress neurobiology: basic concepts and clinical implications. Front Behav Neurosci 12:127. https:\/\/doi.org\/10.3389\/fnbeh.2018.00127","journal-title":"Front Behav Neurosci"},{"key":"9115_CR151","doi-asserted-by":"publisher","first-page":"4245","DOI":"10.1210\/jc.2001-010872","volume":"87","author":"A Buske-Kirschbaum","year":"2002","unstructured":"Buske-Kirschbaum A, Geiben A, H\u00f6llig H, Morschh\u00e4user E, Hellhammer D (2002) Altered responsiveness of the hypothalamus-pituitary-adrenal axis and the sympathetic adrenomedullary system to stress in patients with atopic dermatitis. J Clin Endocrinol Metab 87:4245\u20134251. https:\/\/doi.org\/10.1210\/jc.2001-010872","journal-title":"J Clin Endocrinol Metab"},{"key":"9115_CR152","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1111\/j.1365-2133.2007.07753.x","volume":"156","author":"IM Haeck","year":"2007","unstructured":"Haeck IM et al (2007) Low basal serum cortisol in patients with severe atopic dermatitis: potent topical corticosteroids wrongfully accused. Br J Dermatol 156:979\u2013985. https:\/\/doi.org\/10.1111\/j.1365-2133.2007.07753.x","journal-title":"Br J Dermatol"},{"key":"9115_CR153","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1046\/j.1365-2362.2003.01177.x","volume":"33","author":"H Kimata","year":"2003","unstructured":"Kimata H (2003) Enhancement of allergic skin wheal responses in patients with atopic eczema\/dermatitis syndrome by playing video games or by a frequently ringing mobile phone. Eur J Clin Invest 33:513\u2013517. https:\/\/doi.org\/10.1046\/j.1365-2362.2003.01177.x","journal-title":"Eur J Clin Invest"},{"key":"9115_CR154","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1111\/j.1749-6632.2002.tb04229.x","volume":"966","author":"IJ Elenkov","year":"2002","unstructured":"Elenkov IJ, Chrousos GP (2002) Stress hormones, proinflammatory and antiinflammatory cytokines, and autoimmunity. Ann N Y Acad Sci 966:290\u2013303. https:\/\/doi.org\/10.1111\/j.1749-6632.2002.tb04229.x","journal-title":"Ann N Y Acad Sci"},{"key":"9115_CR155","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1080\/10253890.2020.1859475","volume":"23","author":"JP Herman","year":"2020","unstructured":"Herman JP, Nawreen N, Smail MA, Cotella EM (2020) Brain mechanisms of HPA axis regulation: neurocircuitry and feedback in context Richard Kvetnansky lecture. Stress 23:617\u2013632. https:\/\/doi.org\/10.1080\/10253890.2020.1859475","journal-title":"Stress"},{"key":"9115_CR156","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.1960","volume":"11","author":"R Zefferino","year":"2021","unstructured":"Zefferino R, Di Gioia S, Conese M (2021) Molecular links between endocrine, nervous and immune system during chronic stress. Brain Behav 11:e01960. https:\/\/doi.org\/10.1002\/brb3.1960","journal-title":"Brain Behav"},{"key":"9115_CR157","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1085950","volume":"14","author":"KA James","year":"2023","unstructured":"James KA, Stromin JI, Steenkamp N, Combrinck MI (2023) Understanding the relationships between physiological and psychosocial stress, cortisol and cognition. Front Endocrinol (Lausanne) 14:1085950. https:\/\/doi.org\/10.3389\/fendo.2023.1085950","journal-title":"Front Endocrinol (Lausanne)"},{"key":"9115_CR158","doi-asserted-by":"publisher","DOI":"10.3390\/cells12232726","author":"E Knezevic","year":"2023","unstructured":"Knezevic E, Nenic K, Milanovic V, Knezevic NN (2023) The role of cortisol in chronic stress, neurodegenerative diseases, and psychological disorders. Cells. https:\/\/doi.org\/10.3390\/cells12232726","journal-title":"Cells"},{"key":"9115_CR159","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1111\/j.1365-2133.2009.09518.x","volume":"162","author":"PM H\u00e4gg","year":"2010","unstructured":"H\u00e4gg PM, Hurskainen T, Palatsi R, Ilves M, Oikarinen A (2010) Increased expression of glucocorticoid receptor beta in lymphocytes of patients with severe atopic dermatitis unresponsive to topical corticosteroid. Br J Dermatol 162:318\u2013324. https:\/\/doi.org\/10.1111\/j.1365-2133.2009.09518.x","journal-title":"Br J Dermatol"},{"key":"9115_CR160","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1016\/j.neuron.2010.02.025","volume":"65","author":"SE Ross","year":"2010","unstructured":"Ross SE et al (2010) Loss of inhibitory interneurons in the dorsal spinal cord and elevated itch in Bhlhb5 mutant mice. Neuron 65:886\u2013898. https:\/\/doi.org\/10.1016\/j.neuron.2010.02.025","journal-title":"Neuron"},{"key":"9115_CR161","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.jphs.2020.07.010","volume":"144","author":"M Shiratori-Hayashi","year":"2020","unstructured":"Shiratori-Hayashi M, Tsuda M (2020) Role of reactive astrocytes in the spinal dorsal horn under chronic itch conditions. J Pharmacol Sci 144:147\u2013150. https:\/\/doi.org\/10.1016\/j.jphs.2020.07.010","journal-title":"J Pharmacol Sci"},{"key":"9115_CR162","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1111\/j.1365-2133.2009.09308.x","volume":"161","author":"Y Ishiuji","year":"2009","unstructured":"Ishiuji Y et al (2009) Distinct patterns of brain activity evoked by histamine-induced itch reveal an association with itch intensity and disease severity in atopic dermatitis. Br J Dermatol 161:1072\u20131080. https:\/\/doi.org\/10.1111\/j.1365-2133.2009.09308.x","journal-title":"Br J Dermatol"},{"key":"9115_CR163","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/j.anai.2020.11.008","volume":"126","author":"L Jackson-Cowan","year":"2021","unstructured":"Jackson-Cowan L, Cole EF, Silverberg JI, Lawley LP (2021) Childhood atopic dermatitis is associated with cognitive dysfunction: a National health interview survey study from 2008 to 2018. Ann Allergy Asthma Immunol 126:661\u2013665. https:\/\/doi.org\/10.1016\/j.anai.2020.11.008","journal-title":"Ann Allergy Asthma Immunol"},{"key":"9115_CR164","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1111\/bjd.14697","volume":"175","author":"MA Strom","year":"2016","unstructured":"Strom MA, Fishbein AB, Paller AS, Silverberg JI (2016) Association between atopic dermatitis and attention deficit hyperactivity disorder in U.S. children and adults. Br J Dermatol 175:920\u2013929. https:\/\/doi.org\/10.1111\/bjd.14697","journal-title":"Br J Dermatol"},{"key":"9115_CR165","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1016\/j.jaad.2020.05.041","volume":"83","author":"JI Silverberg","year":"2020","unstructured":"Silverberg JI et al (2020) Association of atopic dermatitis severity with cognitive function in adults. J Am Acad Dermatol 83:1349\u20131359. https:\/\/doi.org\/10.1016\/j.jaad.2020.05.041","journal-title":"J Am Acad Dermatol"},{"key":"9115_CR166","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0292987","volume":"18","author":"Q Zhou","year":"2023","unstructured":"Zhou Q, Yang D, Xiong C, Li X (2023) Atopic dermatitis and cognitive dysfunction in middle-aged and older adults: a systematic review and meta-analysis. PLoS One 18:e0292987. https:\/\/doi.org\/10.1371\/journal.pone.0292987","journal-title":"PLoS One"},{"key":"9115_CR167","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.yfrne.2012.08.006","volume":"33","author":"SD Bilbo","year":"2012","unstructured":"Bilbo SD, Schwarz JM (2012) The immune system and developmental programming of brain and behavior. Front Neuroendocrinol 33:267\u2013286. https:\/\/doi.org\/10.1016\/j.yfrne.2012.08.006","journal-title":"Front Neuroendocrinol"},{"key":"9115_CR168","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.bbi.2021.03.025","volume":"95","author":"MR Breach","year":"2021","unstructured":"Breach MR et al (2021) Maternal allergic inflammation in rats impacts the offspring perinatal neuroimmune milieu and the development of social play, locomotor behavior, and cognitive flexibility. Brain Behav Immun 95:269\u2013286. https:\/\/doi.org\/10.1016\/j.bbi.2021.03.025","journal-title":"Brain Behav Immun"},{"key":"9115_CR169","doi-asserted-by":"publisher","unstructured":"Liu Z et al (2024) Unraveling the causative connection between urticaria, inflammatory cytokines, and mental disorders: perspectives from genetic evidence. Skin Res Technol: Official Journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI) 30:e13906. https:\/\/doi.org\/10.1111\/srt.13906","DOI":"10.1111\/srt.13906"},{"key":"9115_CR170","doi-asserted-by":"publisher","DOI":"10.2340\/actadv.v103.9378","volume":"103","author":"J Zhang","year":"2023","unstructured":"Zhang J, Loman L, Oldhoff JM, Schuttelaar MLA (2023) Beyond anxiety and depression: loneliness and psychiatric disorders in adults with atopic dermatitis. Acta Derm Venereol 103:adv9378. https:\/\/doi.org\/10.2340\/actadv.v103.9378","journal-title":"Acta Derm Venereol"},{"key":"9115_CR171","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1038\/sj.jid.5701079","volume":"128","author":"S Pavlovic","year":"2008","unstructured":"Pavlovic S et al (2008) Further exploring the brain-skin connection: stress worsens dermatitis via substance P-dependent neurogenic inflammation in mice. J Invest Dermatol 128:434\u2013446. https:\/\/doi.org\/10.1038\/sj.jid.5701079","journal-title":"J Invest Dermatol"},{"key":"9115_CR172","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1038\/jid.2010.317","volume":"131","author":"EM Peters","year":"2011","unstructured":"Peters EM et al (2011) Nerve growth factor partially recovers inflamed skin from stress-induced worsening in allergic inflammation. J Invest Dermatol 131:735\u2013743. https:\/\/doi.org\/10.1038\/jid.2010.317","journal-title":"J Invest Dermatol"},{"key":"9115_CR173","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25115738","author":"FR Rommel","year":"2024","unstructured":"Rommel FR et al (2024) Stress affects mast cell proteases in murine skin in a model of atopic dermatitis-like allergic inflammation. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms25115738","journal-title":"Int J Mol Sci"},{"key":"9115_CR174","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1111\/j.1468-3083.2011.04443.x","volume":"27","author":"L Grip","year":"2013","unstructured":"Grip L et al (2013) Substance P alterations in skin and brain of chronically stressed atopic-like mice. J Eur Acad Dermatol Venereol 27:199\u2013205. https:\/\/doi.org\/10.1111\/j.1468-3083.2011.04443.x","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"9115_CR175","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygcen.2023.114289","volume":"339","author":"K Takanami","year":"2023","unstructured":"Takanami K, Morishita M, Sakamoto T, Sakamoto H (2023) Chronic corticosterone exposure evokes itch hypersensitivity and sexual dysfunction in male rats: relationship between the two distinct gastrin-releasing peptide systems in the spinal cord. Gen Comp Endocrinol 339:114289. https:\/\/doi.org\/10.1016\/j.ygcen.2023.114289","journal-title":"Gen Comp Endocrinol"},{"key":"9115_CR176","doi-asserted-by":"publisher","first-page":"7665","DOI":"10.4049\/jimmunol.174.12.7665","volume":"174","author":"J Cao","year":"2005","unstructured":"Cao J et al (2005) Human mast cells express corticotropin-releasing hormone (CRH) receptors and CRH leads to selective secretion of vascular endothelial growth factor. J Immunol 174:7665\u20137675. https:\/\/doi.org\/10.4049\/jimmunol.174.12.7665","journal-title":"J Immunol"},{"key":"9115_CR177","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222112035","author":"HJ Lee","year":"2021","unstructured":"Lee HJ, Hong YJ, Kim M (2021) Angiogenesis in chronic inflammatory skin disorders. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms222112035","journal-title":"Int J Mol Sci"},{"key":"9115_CR178","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1111\/j.0022-202X.2005.23656.x","volume":"124","author":"HJ Park","year":"2005","unstructured":"Park HJ et al (2005) Corticotropin-releasing hormone (CRH) downregulates interleukin-18 expression in human HaCaT keratinocytes by activation of p38 mitogen-activated protein kinase (MAPK) pathway. J Invest Dermatol 124:751\u2013755. https:\/\/doi.org\/10.1111\/j.0022-202X.2005.23656.x","journal-title":"J Invest Dermatol"},{"key":"9115_CR179","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1111\/j.1600-0625.2008.00781.x","volume":"18","author":"HJ Lee","year":"2009","unstructured":"Lee HJ et al (2009) Corticotropin-releasing factor decreases IL-18 in the monocyte-derived dendritic cell. Exp Dermatol 18:199\u2013204. https:\/\/doi.org\/10.1111\/j.1600-0625.2008.00781.x","journal-title":"Exp Dermatol"},{"key":"9115_CR180","doi-asserted-by":"publisher","unstructured":"Oh SH et al (2012) Corticotropin-releasing hormone downregulates IL-10 production by adaptive forkhead box protein 3-negative regulatory T cells in patients with atopic dermatitis. J Allergy Clin Immunol 129:151\u2013159.e151-156. https:\/\/doi.org\/10.1016\/j.jaci.2011.09.008","DOI":"10.1016\/j.jaci.2011.09.008"},{"key":"9115_CR181","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1111\/all.12845","volume":"71","author":"S Jin","year":"2016","unstructured":"Jin S et al (2016) DOCK8: regulator of Treg in response to corticotropin-releasing hormone. Allergy 71:811\u2013819. https:\/\/doi.org\/10.1111\/all.12845","journal-title":"Allergy"},{"key":"9115_CR182","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1159\/000127186","volume":"65","author":"M Kellner","year":"1997","unstructured":"Kellner M et al (1997) Corticotropin-releasing hormone inhibits melatonin secretion in healthy volunteers\u2013a potential link to low-melatonin syndrome in depression? Neuroendocrinology 65:284\u2013290. https:\/\/doi.org\/10.1159\/000127186","journal-title":"Neuroendocrinology"},{"key":"9115_CR183","doi-asserted-by":"publisher","first-page":"514","DOI":"10.2174\/1570159x1304150831120428","volume":"13","author":"GJ Peng","year":"2015","unstructured":"Peng GJ, Tian JS, Gao XX, Zhou YZ, Qin XM (2015) Research on the pathological mechanism and drug treatment mechanism of depression. Curr Neuropharmacol 13:514\u2013523. https:\/\/doi.org\/10.2174\/1570159x1304150831120428","journal-title":"Curr Neuropharmacol"},{"key":"9115_CR184","doi-asserted-by":"publisher","first-page":"2814","DOI":"10.1038\/jid.2015.223","volume":"135","author":"H Mochizuki","year":"2015","unstructured":"Mochizuki H et al (2015) Scratching induces overactivity in motor-related regions and reward system in chronic itch patients. J Invest Dermatol 135:2814\u20132823. https:\/\/doi.org\/10.1038\/jid.2015.223","journal-title":"J Invest Dermatol"},{"key":"9115_CR185","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1093\/cercor\/bhs363","volume":"24","author":"V Napadow","year":"2014","unstructured":"Napadow V et al (2014) The brain circuitry mediating antipruritic effects of acupuncture. Cereb Cortex 24:873\u2013882. https:\/\/doi.org\/10.1093\/cercor\/bhs363","journal-title":"Cereb Cortex"},{"key":"9115_CR186","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1007\/s00403-013-1325-x","volume":"305","author":"A Rasul","year":"2013","unstructured":"Rasul A et al (2013) Chronic mild stress modulates 5-HT1A and 5-HT2A receptor expression in the cerebellar cortex of NC\/Nga atopic-like mice. Arch Dermatol Res 305:407\u2013413. https:\/\/doi.org\/10.1007\/s00403-013-1325-x","journal-title":"Arch Dermatol Res"},{"key":"9115_CR187","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2019.109818","volume":"98","author":"M Yeom","year":"2020","unstructured":"Yeom M et al (2020) Atopic dermatitis induces anxiety- and depressive-like behaviors with concomitant neuronal adaptations in brain reward circuits in mice. Prog Neuropsychopharmacol Biol Psychiatry 98:109818. https:\/\/doi.org\/10.1016\/j.pnpbp.2019.109818","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"9115_CR188","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s12272-022-01369-3","volume":"45","author":"B Yang","year":"2022","unstructured":"Yang B, Ryu JS, Rim C, Shin JU, Kwon MS (2022) Possible role of arginase 1 positive microglia on depressive\/anxiety-like behaviors in atopic dermatitis mouse model. Arch Pharm Res 45:11\u201328. https:\/\/doi.org\/10.1007\/s12272-022-01369-3","journal-title":"Arch Pharm Res"},{"key":"9115_CR189","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-33317-x","volume":"8","author":"G Park","year":"2018","unstructured":"Park G, Jung YS, Park MK, Yang CH, Kim YU (2018) Melatonin inhibits attention-deficit\/hyperactivity disorder caused by atopic dermatitis-induced psychological stress in an NC\/Nga atopic-like mouse model. Sci Rep 8:14981. https:\/\/doi.org\/10.1038\/s41598-018-33317-x","journal-title":"Sci Rep"},{"key":"9115_CR190","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24065942","author":"S Iida","year":"2023","unstructured":"Iida S et al (2023) Inflammatory skin disease causes anxiety symptoms leading to an irreversible course. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms24065942","journal-title":"Int J Mol Sci"},{"key":"9115_CR191","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1006\/brbi.2000.0604","volume":"14","author":"MS Flint","year":"2000","unstructured":"Flint MS, Miller DB, Tinkle SS (2000) Restraint-induced modulation of allergic and irritant contact dermatitis in male and female B6.129 mice. Brain Behav Immun 14:256\u2013269. https:\/\/doi.org\/10.1006\/brbi.2000.0604","journal-title":"Brain Behav Immun"},{"key":"9115_CR192","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1111\/j.1365-2133.2004.05980.x","volume":"151","author":"Y Nakano","year":"2004","unstructured":"Nakano Y (2004) Stress-induced modulation of skin immune function: two types of antigen-presenting cells in the epidermis are differentially regulated by chronic stress. Br J Dermatol 151:50\u201364. https:\/\/doi.org\/10.1111\/j.1365-2133.2004.05980.x","journal-title":"Br J Dermatol"},{"key":"9115_CR193","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1034\/j.1600-0625.2003.120106.x","volume":"12","author":"K Kaneko","year":"2003","unstructured":"Kaneko K, Kawana S, Arai K, Shibasaki T (2003) Corticotropin-releasing factor receptor type 1 is involved in the stress-induced exacerbation of chronic contact dermatitis in rats. Exp Dermatol 12:47\u201352. https:\/\/doi.org\/10.1034\/j.1600-0625.2003.120106.x","journal-title":"Exp Dermatol"},{"key":"9115_CR194","doi-asserted-by":"publisher","first-page":"187","DOI":"10.2353\/ajpath.2010.090322","volume":"176","author":"SJ Bae","year":"2010","unstructured":"Bae SJ et al (2010) Involvement of L-selectin in contact hypersensitivity responses augmented by auditory stress. Am J Pathol 176:187\u2013197. https:\/\/doi.org\/10.2353\/ajpath.2010.090322","journal-title":"Am J Pathol"},{"key":"9115_CR195","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1080\/1025389031000088426","volume":"6","author":"MS Flint","year":"2003","unstructured":"Flint MS, Morgan JB, Shreve SN, Tinkle SS (2003) Restraint stress and corticotropin releasing hormone modulation of murine cutaneous POMC mRNA. Stress 6:59\u201362. https:\/\/doi.org\/10.1080\/1025389031000088426","journal-title":"Stress"},{"key":"9115_CR196","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1111\/j.1346-8138.2009.00771.x","volume":"37","author":"J Zhang","year":"2010","unstructured":"Zhang J et al (2010) Acute stress enhances contact dermatitis by promoting nuclear factor-kappaB DNA-binding activity and interleukin-18 expression in mice. J Dermatol 37:512\u2013521. https:\/\/doi.org\/10.1111\/j.1346-8138.2009.00771.x","journal-title":"J Dermatol"},{"key":"9115_CR197","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.bbi.2013.10.027","volume":"36","author":"JM Hall","year":"2014","unstructured":"Hall JM et al (2014) Chronic psychological stress suppresses contact hypersensitivity: potential roles of dysregulated cell trafficking and decreased IFN-\u03b3 production. Brain Behav Immun 36:156\u2013164. https:\/\/doi.org\/10.1016\/j.bbi.2013.10.027","journal-title":"Brain Behav Immun"},{"key":"9115_CR198","doi-asserted-by":"publisher","first-page":"848","DOI":"10.4049\/jimmunol.0903878","volume":"186","author":"S Pavlovic","year":"2011","unstructured":"Pavlovic S et al (2011) Substance P is a key mediator of stress-induced protection from allergic sensitization via modified antigen presentation. J Immunol 186:848\u2013855. https:\/\/doi.org\/10.4049\/jimmunol.0903878","journal-title":"J Immunol"},{"key":"9115_CR199","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1111\/j.0022-202X.2005.23913.x","volume":"125","author":"N Papadopoulou","year":"2005","unstructured":"Papadopoulou N, Kalogeromitros D, Staurianeas NG, Tiblalexi D, Theoharides TC (2005) Corticotropin-releasing hormone receptor-1 and histidine decarboxylase expression in chronic urticaria. J Invest Dermatol 125:952\u2013955. https:\/\/doi.org\/10.1111\/j.0022-202X.2005.23913.x","journal-title":"J Invest Dermatol"},{"key":"9115_CR200","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1111\/j.1365-2222.2007.02864.x","volume":"38","author":"SM Dyke","year":"2008","unstructured":"Dyke SM, Carey BS, Kaminski ER (2008) Effect of stress on basophil function in chronic idiopathic urticaria. Clin Experimental Allergy: J Br Soc Allergy Clin Immunol 38:86\u201392. https:\/\/doi.org\/10.1111\/j.1365-2222.2007.02864.x","journal-title":"Clin Experimental Allergy: J Br Soc Allergy Clin Immunol"},{"key":"9115_CR201","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1213138","volume":"14","author":"D Wiebe","year":"2023","unstructured":"Wiebe D, Limberg MM, Gray N, Raap U (2023) Basophils in pruritic skin diseases. Front Immunol 14:1213138. https:\/\/doi.org\/10.3389\/fimmu.2023.1213138","journal-title":"Front Immunol"},{"key":"9115_CR202","doi-asserted-by":"publisher","unstructured":"Varghese R et al (2016) Association among stress, hypocortisolism, systemic inflammation, and disease severity in chronic urticaria. Ann Allergy, Asthma Immunol: official publication of the American College of Allergy, Asthma, & Immunology 116:344\u2013348.e341. https:\/\/doi.org\/10.1016\/j.anai.2016.01.016","DOI":"10.1016\/j.anai.2016.01.016"},{"key":"9115_CR203","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1515\/tjb-2020-0304","volume":"46","author":"E Vurgun","year":"2021","unstructured":"Vurgun E, Memet B, Kocaturk E, Guntas G (2021) Evaluation of serum 25-hydroxyvitamin D levels and cortisol\/dehydroepiandrosterone sulfate ratio in chronic spontaneous urticaria. Turk J Biochem 46:191\u2013196. https:\/\/doi.org\/10.1515\/tjb-2020-0304","journal-title":"Turk J Biochem"},{"key":"9115_CR204","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.667978","volume":"12","author":"B Memet","year":"2021","unstructured":"Memet B et al (2021) In chronic spontaneous urticaria, comorbid depression linked to higher disease activity, and substance P levels. Front Psychiatry 12:667978. https:\/\/doi.org\/10.3389\/fpsyt.2021.667978","journal-title":"Front Psychiatry"},{"key":"9115_CR205","doi-asserted-by":"publisher","DOI":"10.1186\/s13601-019-0278-3","volume":"9","author":"GN Konstantinou","year":"2019","unstructured":"Konstantinou GN, Konstantinou GN (2019) Psychiatric comorbidity in chronic urticaria patients: a systematic review and meta-analysis. Clin Transl Allergy 9:42. https:\/\/doi.org\/10.1186\/s13601-019-0278-3","journal-title":"Clin Transl Allergy"},{"key":"9115_CR206","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1111\/j.1365-2133.2010.10138.x","volume":"164","author":"S Herg\u00fcner","year":"2011","unstructured":"Herg\u00fcner S et al (2011) Levels of depression, anxiety and behavioural problems and frequency of psychiatric disorders in children with chronic idiopathic urticaria. Br J Dermatol 164:1342\u20131347. https:\/\/doi.org\/10.1111\/j.1365-2133.2010.10138.x","journal-title":"Br J Dermatol"},{"key":"9115_CR207","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-025-03397-4","volume":"22","author":"S Yang","year":"2025","unstructured":"Yang S et al (2025) Beyond the itch: the complex interplay of immune, neurological, and psychological factors in chronic urticaria. J Neuroinflammation 22:75. https:\/\/doi.org\/10.1186\/s12974-025-03397-4","journal-title":"J Neuroinflammation"},{"key":"9115_CR208","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.p1538","volume":"382","author":"SJ Matthews","year":"2023","unstructured":"Matthews SJ, Housam N, Lawton S, Taverner P (2023) Atopic eczema in under 12s: diagnosis and management-summary of updated NICE guidance. BMJ 382:1538. https:\/\/doi.org\/10.1136\/bmj.p1538","journal-title":"BMJ"},{"key":"9115_CR209","doi-asserted-by":"publisher","first-page":"e43","DOI":"10.1016\/j.jaad.2023.08.102","volume":"90","author":"DMR Davis","year":"2024","unstructured":"Davis DMR et al (2024) Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies. J Am Acad Dermatol 90:e43\u2013e56. https:\/\/doi.org\/10.1016\/j.jaad.2023.08.102","journal-title":"J Am Acad Dermatol"},{"key":"9115_CR210","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","volume":"375","author":"EL Simpson","year":"2016","unstructured":"Simpson EL et al (2016) Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med 375:2335\u20132348. https:\/\/doi.org\/10.1056\/NEJMoa1610020","journal-title":"N Engl J Med"},{"key":"9115_CR211","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1016\/j.jaad.2020.06.054","volume":"83","author":"AS Paller","year":"2020","unstructured":"Paller AS et al (2020) Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: a randomized, double-blinded, placebo-controlled phase 3 trial. J Am Acad Dermatol 83:1282\u20131293. https:\/\/doi.org\/10.1016\/j.jaad.2020.06.054","journal-title":"J Am Acad Dermatol"},{"key":"9115_CR212","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1001\/jamadermatol.2019.3336","volume":"156","author":"EL Simpson","year":"2020","unstructured":"Simpson EL et al (2020) Efficacy and safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis: a phase 3 randomized clinical trial. JAMA Dermatol 156:44\u201356. https:\/\/doi.org\/10.1001\/jamadermatol.2019.3336","journal-title":"JAMA Dermatol"},{"key":"9115_CR213","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/s0140-6736(22)01539-2","volume":"400","author":"AS Paller","year":"2022","unstructured":"Paller AS et al (2022) Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 400:908\u2013919. https:\/\/doi.org\/10.1016\/s0140-6736(22)01539-2","journal-title":"Lancet"},{"key":"9115_CR214","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2024.110721","volume":"27","author":"W Liu","year":"2024","unstructured":"Liu W et al (2024) Stapokibart (CM310) targets IL-4R\u03b1 for the treatment of type 2 inflammation. iScience 27:110721. https:\/\/doi.org\/10.1016\/j.isci.2024.110721","journal-title":"iScience"},{"key":"9115_CR215","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1097\/cm9.0000000000002747","volume":"137","author":"Y Zhao","year":"2024","unstructured":"Zhao Y et al (2024) Efficacy and safety of CM310 in moderate-to-severe atopic dermatitis: a multicenter, randomized, double-blind, placebo-controlled phase 2b trial. Chin Med J (Engl) 137:200\u2013208. https:\/\/doi.org\/10.1097\/cm9.0000000000002747","journal-title":"Chin Med J (Engl)"},{"key":"9115_CR216","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1111\/all.16368","volume":"80","author":"Y Zhao","year":"2025","unstructured":"Zhao Y et al (2025) Long-term efficacy and safety of stapokibart for moderate-to-severe atopic dermatitis: 52-week results from a phase 3 trial. Allergy 80:1348\u20131357. https:\/\/doi.org\/10.1111\/all.16368","journal-title":"Allergy"},{"key":"9115_CR217","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1016\/j.jaci.2023.11.924","volume":"153","author":"JI Silverberg","year":"2024","unstructured":"Silverberg JI et al (2024) Efficacy and safety of Rademikibart (CBP-201), a next-generation mAb targeting IL-4R\u03b1, in adults with moderate to severe atopic dermatitis: A phase 2 randomized trial (CBP-201-WW001). J Allergy Clin Immunol 153:1040\u20131049e1012. https:\/\/doi.org\/10.1016\/j.jaci.2023.11.924","journal-title":"J Allergy Clin Immunol"},{"key":"9115_CR218","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.jmb.2016.12.005","volume":"429","author":"B Popovic","year":"2017","unstructured":"Popovic B et al (2017) Structural characterisation reveals mechanism of IL-13-neutralising monoclonal antibody tralokinumab as inhibition of binding to IL-13R\u03b11 and IL-13R\u03b12. J Mol Biol 429:208\u2013219. https:\/\/doi.org\/10.1016\/j.jmb.2016.12.005","journal-title":"J Mol Biol"},{"key":"9115_CR219","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1111\/bjd.19574","volume":"184","author":"A Wollenberg","year":"2021","unstructured":"Wollenberg A et al (2021) Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2). Br J Dermatol 184:437\u2013449. https:\/\/doi.org\/10.1111\/bjd.19574","journal-title":"Br J Dermatol"},{"key":"9115_CR220","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1111\/bjd.19573","volume":"184","author":"JI Silverberg","year":"2021","unstructured":"Silverberg JI et al (2021) Tralokinumab plus topical corticosteroids for the treatment of moderate-to-severe atopic dermatitis: results from the double-blind, randomized, multicentre, placebo-controlled phase III ECZTRA 3 trial. Br J Dermatol 184:450\u2013463. https:\/\/doi.org\/10.1111\/bjd.19573","journal-title":"Br J Dermatol"},{"key":"9115_CR221","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1111\/bjd.20832","volume":"186","author":"J Gutermuth","year":"2022","unstructured":"Gutermuth J et al (2022) Tralokinumab plus topical corticosteroids in adults with severe atopic dermatitis and inadequate response to or intolerance of ciclosporin A: a placebo-controlled, randomized, phase III clinical trial (ECZTRA 7). Br J Dermatol 186:440\u2013452. https:\/\/doi.org\/10.1111\/bjd.20832","journal-title":"Br J Dermatol"},{"key":"9115_CR222","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1001\/jamadermatol.2023.0627","volume":"159","author":"AS Paller","year":"2023","unstructured":"Paller AS et al (2023) Efficacy and safety of tralokinumab in adolescents with moderate to severe atopic dermatitis: the phase 3 ECZTRA 6 randomized clinical trial. JAMA Dermatol 159:596\u2013605. https:\/\/doi.org\/10.1001\/jamadermatol.2023.0627","journal-title":"JAMA Dermatol"},{"key":"9115_CR223","doi-asserted-by":"publisher","first-page":"2555","DOI":"10.1111\/all.15326","volume":"77","author":"PM Hansen","year":"2022","unstructured":"Hansen PM et al (2022) IL-4 and IL-13 both contribute to the homeostasis of human conjunctival goblet cells in vitro. Allergy 77:2555\u20132558. https:\/\/doi.org\/10.1111\/all.15326","journal-title":"Allergy"},{"key":"9115_CR224","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1111\/bjd.21867","volume":"187","author":"EL Simpson","year":"2022","unstructured":"Simpson EL et al (2022) Safety of tralokinumab in adult patients with moderate-to-severe atopic dermatitis: pooled analysis of five randomized, double-blind, placebo-controlled phase II and phase III trials. Br J Dermatol 187:888\u2013899. https:\/\/doi.org\/10.1111\/bjd.21867","journal-title":"Br J Dermatol"},{"key":"9115_CR225","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/j.jaad.2022.11.047","volume":"88","author":"LA Beck","year":"2023","unstructured":"Beck LA et al (2023) Tralokinumab treatment improves the skin microbiota by increasing the microbial diversity in adults with moderate-to-severe atopic dermatitis: analysis of microbial diversity in ECZTRA 1, a randomized controlled trial. J Am Acad Dermatol 88:816\u2013823. https:\/\/doi.org\/10.1016\/j.jaad.2022.11.047","journal-title":"J Am Acad Dermatol"},{"key":"9115_CR226","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1111\/all.16108","volume":"79","author":"E Guttman-Yassky","year":"2024","unstructured":"Guttman-Yassky E et al (2024) Targeting IL-13 with tralokinumab normalizes type 2 inflammation in atopic dermatitis both early and at 2 years. Allergy 79:1560\u20131572. https:\/\/doi.org\/10.1111\/all.16108","journal-title":"Allergy"},{"key":"9115_CR227","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1016\/j.jmb.2013.01.024","volume":"425","author":"M Ultsch","year":"2013","unstructured":"Ultsch M et al (2013) Structural basis of signaling blockade by anti-IL-13 antibody Lebrikizumab. J Mol Biol 425:1330\u20131339. https:\/\/doi.org\/10.1016\/j.jmb.2013.01.024","journal-title":"J Mol Biol"},{"key":"9115_CR228","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1001\/jamadermatol.2020.0079","volume":"156","author":"E Guttman-Yassky","year":"2020","unstructured":"Guttman-Yassky E et al (2020) Efficacy and safety of Lebrikizumab, a High-Affinity Interleukin 13 Inhibitor, in adults with moderate to severe atopic dermatitis: a phase 2b randomized clinical trial. JAMA Dermatol 156:411\u2013420. https:\/\/doi.org\/10.1001\/jamadermatol.2020.0079","journal-title":"JAMA Dermatol"},{"key":"9115_CR229","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1001\/jamadermatol.2022.5534","volume":"159","author":"EL Simpson","year":"2023","unstructured":"Simpson EL et al (2023) Efficacy and safety of lebrikizumab in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis: a randomized clinical trial (ADhere). JAMA Dermatol 159:182\u2013191. https:\/\/doi.org\/10.1001\/jamadermatol.2022.5534","journal-title":"JAMA Dermatol"},{"key":"9115_CR230","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1093\/bjd\/ljad022","volume":"188","author":"A Blauvelt","year":"2023","unstructured":"Blauvelt A et al (2023) Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials. Br J Dermatol 188:740\u2013748. https:\/\/doi.org\/10.1093\/bjd\/ljad022","journal-title":"Br J Dermatol"},{"key":"9115_CR231","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1056\/NEJMoa2206714","volume":"388","author":"JI Silverberg","year":"2023","unstructured":"Silverberg JI et al (2023) Two phase 3 trials of lebrikizumab for moderate-to-severe atopic dermatitis. N Engl J Med 388:1080\u20131091. https:\/\/doi.org\/10.1056\/NEJMoa2206714","journal-title":"N Engl J Med"},{"key":"9115_CR232","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1001\/jamadermatol.2024.2192","volume":"160","author":"AM Drucker","year":"2024","unstructured":"Drucker AM et al (2024) Systemic immunomodulatory treatments for atopic dermatitis: living systematic review and network meta-analysis update. JAMA Dermatol 160:936\u2013944. https:\/\/doi.org\/10.1001\/jamadermatol.2024.2192","journal-title":"JAMA Dermatol"},{"key":"9115_CR233","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1016\/j.jaad.2024.12.026","volume":"92","author":"E Guttman-Yassky","year":"2025","unstructured":"Guttman-Yassky E et al (2025) The efficacy of longer-term lebrikizumab treatment in patients with moderate-to-severe atopic dermatitis who did not meet protocol-defined response criteria at week 16 in 2 randomized controlled clinical trials. J Am Acad Dermatol 92:1024\u20131031. https:\/\/doi.org\/10.1016\/j.jaad.2024.12.026","journal-title":"J Am Acad Dermatol"},{"key":"9115_CR234","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1007\/s40257-023-00792-6","volume":"24","author":"L Stein Gold","year":"2023","unstructured":"Stein Gold L et al (2023) Safety of lebrikizumab in adults and adolescents with moderate-to-severe atopic dermatitis: an integrated analysis of eight clinical trials. Am J Clin Dermatol 24:595\u2013607. https:\/\/doi.org\/10.1007\/s40257-023-00792-6","journal-title":"Am J Clin Dermatol"},{"key":"9115_CR235","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1001\/jamadermatol.2024.2131","volume":"160","author":"A Blauvelt","year":"2024","unstructured":"Blauvelt A et al (2024) Cendakimab in patients with moderate to severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol 160:856\u2013864. https:\/\/doi.org\/10.1001\/jamadermatol.2024.2131","journal-title":"JAMA Dermatol"},{"key":"9115_CR236","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/j.jaad.2023.10.026","volume":"90","author":"KA Veverka","year":"2024","unstructured":"Veverka KA et al (2024) Safety and efficacy of eblasakimab, an interleukin 13 receptor \u03b11 monoclonal antibody, in adults with moderate-to-severe atopic dermatitis: a phase 1b, multiple-ascending dose study. J Am Acad Dermatol 90:504\u2013511. https:\/\/doi.org\/10.1016\/j.jaad.2023.10.026","journal-title":"J Am Acad Dermatol"},{"key":"9115_CR237","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1056\/NEJMoa1606490","volume":"376","author":"T Ruzicka","year":"2017","unstructured":"Ruzicka T et al (2017) Anti-interleukin-31 receptor A antibody for atopic dermatitis. N Engl J Med 376:826\u2013835. https:\/\/doi.org\/10.1056\/NEJMoa1606490","journal-title":"N Engl J Med"},{"key":"9115_CR238","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1016\/j.jaci.2018.03.018","volume":"142","author":"K Kabashima","year":"2018","unstructured":"Kabashima K et al (2018) Nemolizumab in patients with moderate-to-severe atopic dermatitis: Randomized, phase II, long-term extension study. J Allergy Clin Immunol 142:1121\u20131130e1127. https:\/\/doi.org\/10.1016\/j.jaci.2018.03.018","journal-title":"J Allergy Clin Immunol"},{"key":"9115_CR239","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1056\/NEJMoa1917006","volume":"383","author":"K Kabashima","year":"2020","unstructured":"Kabashima K, Matsumura T, Komazaki H, Kawashima M (2020) Trial of nemolizumab and topical agents for atopic dermatitis with pruritus. N Engl J Med 383:141\u2013150. https:\/\/doi.org\/10.1056\/NEJMoa1917006","journal-title":"N Engl J Med"},{"key":"9115_CR240","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1111\/bjd.20873","volume":"186","author":"K Kabashima","year":"2022","unstructured":"Kabashima K, Matsumura T, Komazaki H, Kawashima M (2022) Nemolizumab plus topical agents in patients with atopic dermatitis (AD) and moderate-to-severe pruritus provide improvement in pruritus and signs of AD for up to 68 weeks: results from two phase III, long-term studies. Br J Dermatol 186:642\u2013651. https:\/\/doi.org\/10.1111\/bjd.20873","journal-title":"Br J Dermatol"},{"key":"9115_CR241","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1093\/bjd\/ljad268","volume":"190","author":"A Igarashi","year":"2023","unstructured":"Igarashi A, Katsunuma T, Matsumura T, Komazaki H (2023) Efficacy and safety of nemolizumab in paediatric patients aged 6\u201312\u2005years with atopic dermatitis with moderate-to-severe pruritus: results from a phase III, randomized, double-blind, placebo-controlled, multicentre study. Br J Dermatol 190:20\u201328. https:\/\/doi.org\/10.1093\/bjd\/ljad268","journal-title":"Br J Dermatol"},{"key":"9115_CR242","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1093\/bjd\/ljae458","volume":"192","author":"A Igarashi","year":"2025","unstructured":"Igarashi A, Katsunuma T, Nagano Y, Komazaki H (2025) Long-term (68 weeks) administration of nemolizumab in paediatric patients aged 6\u201312\u2005years with atopic dermatitis with moderate-to-severe pruritus: efficacy and safety data from a phase III study. Br J Dermatol 192:837\u2013844. https:\/\/doi.org\/10.1093\/bjd\/ljae458","journal-title":"Br J Dermatol"},{"key":"9115_CR243","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/s0140-6736(24)01203-0","volume":"404","author":"JI Silverberg","year":"2024","unstructured":"Silverberg JI et al (2024) Nemolizumab with concomitant topical therapy in adolescents and adults with moderate-to-severe atopic dermatitis (ARCADIA 1 and ARCADIA 2): results from two replicate, double-blind, randomised controlled phase 3 trials. Lancet 404:445\u2013460. https:\/\/doi.org\/10.1016\/s0140-6736(24)01203-0","journal-title":"Lancet"},{"key":"9115_CR244","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/j.jaad.2018.11.059","volume":"80","author":"EL Simpson","year":"2019","unstructured":"Simpson EL et al (2019) Tezepelumab, an anti-thymic stromal lymphopoietin monoclonal antibody, in the treatment of moderate to severe atopic dermatitis: a randomized phase 2a clinical trial. J Am Acad Dermatol 80:1013\u20131021. https:\/\/doi.org\/10.1016\/j.jaad.2018.11.059","journal-title":"J Am Acad Dermatol"},{"key":"9115_CR245","first-page":"318","volume":"34","author":"JA Hodge","year":"2016","unstructured":"Hodge JA et al (2016) The mechanism of action of tofacitinib - an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis. Clin Exp Rheumatol 34:318\u2013328","journal-title":"Clin Exp Rheumatol"},{"key":"9115_CR246","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1111\/bjd.14871","volume":"175","author":"R Bissonnette","year":"2016","unstructured":"Bissonnette R et al (2016) Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial. Br J Dermatol 175:902\u2013911. https:\/\/doi.org\/10.1111\/bjd.14871","journal-title":"Br J Dermatol"},{"key":"9115_CR247","doi-asserted-by":"publisher","first-page":"3109","DOI":"10.1182\/blood-2009-04-214957","volume":"115","author":"A Quint\u00e1s-Cardama","year":"2010","unstructured":"Quint\u00e1s-Cardama A et al (2010) Preclinical characterization of the selective JAK1\/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood 115:3109\u20133117. https:\/\/doi.org\/10.1182\/blood-2009-04-214957","journal-title":"Blood"},{"key":"9115_CR248","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/j.jaci.2019.08.042","volume":"145","author":"BS Kim","year":"2020","unstructured":"Kim BS et al (2020) Treatment of atopic dermatitis with ruxolitinib cream (JAK1\/JAK2 inhibitor) or triamcinolone cream. J Allergy Clin Immunol 145:572\u2013582. https:\/\/doi.org\/10.1016\/j.jaci.2019.08.042","journal-title":"J Allergy Clin Immunol"},{"key":"9115_CR249","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1016\/j.jaad.2020.02.009","volume":"82","author":"BS Kim","year":"2020","unstructured":"Kim BS et al (2020) Effects of ruxolitinib cream on pruritus and quality of life in atopic dermatitis: results from a phase 2, randomized, dose-ranging, vehicle- and active-controlled study. J Am Acad Dermatol 82:1305\u20131313. https:\/\/doi.org\/10.1016\/j.jaad.2020.02.009","journal-title":"J Am Acad Dermatol"},{"key":"9115_CR250","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/j.jaad.2021.04.085","volume":"85","author":"K Papp","year":"2021","unstructured":"Papp K et al (2021) Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: results from 2 phase 3, randomized, double-blind studies. J Am Acad Dermatol 85:863\u2013872. https:\/\/doi.org\/10.1016\/j.jaad.2021.04.085","journal-title":"J Am Acad Dermatol"},{"key":"9115_CR251","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1111\/jdv.18571","volume":"37","author":"A Blauvelt","year":"2023","unstructured":"Blauvelt A et al (2023) Rapid pruritus reduction with ruxolitinib cream treatment in patients with atopic dermatitis. J Eur Acad Dermatol Venereol 37:137\u2013146. https:\/\/doi.org\/10.1111\/jdv.18571","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"9115_CR252","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1016\/j.jaad.2022.09.060","volume":"88","author":"K Papp","year":"2023","unstructured":"Papp K et al (2023) Long-term safety and disease control with ruxolitinib cream in atopic dermatitis: results from two phase 3 studies. J Am Acad Dermatol 88:1008\u20131016. https:\/\/doi.org\/10.1016\/j.jaad.2022.09.060","journal-title":"J Am Acad Dermatol"},{"key":"9115_CR253","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1111\/bjd.16014","volume":"178","author":"H Nakagawa","year":"2018","unstructured":"Nakagawa H, Nemoto O, Igarashi A, Nagata T (2018) Efficacy and safety of topical JTE-052, a Janus kinase inhibitor, in Japanese adult patients with moderate-to-severe atopic dermatitis: a phase II, multicentre, randomized, vehicle-controlled clinical study. Br J Dermatol 178:424\u2013432. https:\/\/doi.org\/10.1111\/bjd.16014","journal-title":"Br J Dermatol"},{"key":"9115_CR254","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1016\/j.jaci.2019.08.004","volume":"144","author":"H Nakagawa","year":"2019","unstructured":"Nakagawa H et al (2019) Phase 2 clinical study of delgocitinib ointment in pediatric patients with atopic dermatitis. J Allergy Clin Immunol 144:1575\u20131583. https:\/\/doi.org\/10.1016\/j.jaci.2019.08.004","journal-title":"J Allergy Clin Immunol"},{"key":"9115_CR255","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/j.jaad.2019.12.015","volume":"82","author":"H Nakagawa","year":"2020","unstructured":"Nakagawa H et al (2020) Delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with moderate to severe atopic dermatitis: A phase 3, randomized, double-blind, vehicle-controlled study and an open-label, long-term extension study. J Am Acad Dermatol 82:823\u2013831. https:\/\/doi.org\/10.1016\/j.jaad.2019.12.015","journal-title":"J Am Acad Dermatol"},{"key":"9115_CR256","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1016\/j.jaad.2021.06.014","volume":"85","author":"H Nakagawa","year":"2021","unstructured":"Nakagawa H et al (2021) Delgocitinib ointment in pediatric patients with atopic dermatitis: A phase 3, randomized, double-blind, vehicle-controlled study and a subsequent open-label, long-term study. J Am Acad Dermatol 85:854\u2013862. https:\/\/doi.org\/10.1016\/j.jaad.2021.06.014","journal-title":"J Am Acad Dermatol"},{"key":"9115_CR257","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1111\/bjd.21826","volume":"187","author":"MN Landis","year":"2022","unstructured":"Landis MN et al (2022) Efficacy and safety of topical brepocitinib for the treatment of mild-to-moderate atopic dermatitis: a phase IIb, randomized, double-blind, vehicle-controlled, dose-ranging and parallel-group study. Br J Dermatol 187:878\u2013887. https:\/\/doi.org\/10.1111\/bjd.21826","journal-title":"Br J Dermatol"},{"key":"9115_CR258","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1001\/jamadermatol.2019.2855","volume":"155","author":"MJ Gooderham","year":"2019","unstructured":"Gooderham MJ et al (2019) Efficacy and safety of oral Janus kinase 1 inhibitor abrocitinib for patients with atopic dermatitis: A phase 2 randomized clinical trial. JAMA Dermatol 155:1371\u20131379. https:\/\/doi.org\/10.1001\/jamadermatol.2019.2855","journal-title":"JAMA Dermatol"},{"key":"9115_CR259","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1001\/jamadermatol.2020.1406","volume":"156","author":"JI Silverberg","year":"2020","unstructured":"Silverberg JI et al (2020) Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis: A randomized clinical trial. JAMA Dermatol 156:863\u2013873. https:\/\/doi.org\/10.1001\/jamadermatol.2020.1406","journal-title":"JAMA Dermatol"},{"key":"9115_CR260","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/s0140-6736(20)30732-7","volume":"396","author":"EL Simpson","year":"2020","unstructured":"Simpson EL et al (2020) Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet 396:255\u2013266. https:\/\/doi.org\/10.1016\/s0140-6736(20)30732-7","journal-title":"Lancet"},{"key":"9115_CR261","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1001\/jamadermatol.2021.2830","volume":"157","author":"LF Eichenfield","year":"2021","unstructured":"Eichenfield LF et al (2021) Efficacy and safety of abrocitinib in combination with topical therapy in adolescents with moderate-to-severe atopic dermatitis: the JADE TEEN randomized clinical trial. JAMA Dermatol 157:1165\u20131173. https:\/\/doi.org\/10.1001\/jamadermatol.2021.2830","journal-title":"JAMA Dermatol"},{"key":"9115_CR262","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.jaad.2021.05.075","volume":"86","author":"A Blauvelt","year":"2022","unstructured":"Blauvelt A et al (2022) Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate-to-severe atopic dermatitis: results from the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) REGIMEN phase 3 trial. J Am Acad Dermatol 86:104\u2013112. https:\/\/doi.org\/10.1016\/j.jaad.2021.05.075","journal-title":"J Am Acad Dermatol"},{"key":"9115_CR263","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1056\/NEJMoa2019380","volume":"384","author":"T Bieber","year":"2021","unstructured":"Bieber T et al (2021) Abrocitinib versus placebo or dupilumab for atopic dermatitis. N Engl J Med 384:1101\u20131112. https:\/\/doi.org\/10.1056\/NEJMoa2019380","journal-title":"N Engl J Med"},{"key":"9115_CR264","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/j.jaci.2019.11.025","volume":"145","author":"E Guttman-Yassky","year":"2020","unstructured":"Guttman-Yassky E et al (2020) Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial. J Allergy Clin Immunol 145:877\u2013884. https:\/\/doi.org\/10.1016\/j.jaci.2019.11.025","journal-title":"J Allergy Clin Immunol"},{"key":"9115_CR265","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1016\/s0140-6736(21)00588-2","volume":"397","author":"E Guttman-Yassky","year":"2021","unstructured":"Guttman-Yassky E et al (2021) Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials. Lancet 397:2151\u20132168. https:\/\/doi.org\/10.1016\/s0140-6736(21)00588-2","journal-title":"Lancet"},{"key":"9115_CR266","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s40257-024-00853-4","volume":"25","author":"JI Silverberg","year":"2024","unstructured":"Silverberg JI et al (2024) Early and sustained improvements in symptoms and quality of life with upadacitinib in adults and adolescents with moderate-to-severe atopic dermatitis: 52-week results from two phase III randomized clinical trials (Measure up 1 and measure up 2). Am J Clin Dermatol 25:485\u2013496. https:\/\/doi.org\/10.1007\/s40257-024-00853-4","journal-title":"Am J Clin Dermatol"},{"key":"9115_CR267","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/j.jaci.2021.07.036","volume":"149","author":"JI Silverberg","year":"2022","unstructured":"Silverberg JI et al (2022) Upadacitinib plus topical corticosteroids in atopic dermatitis: week 52 AD up study results. J Allergy Clin Immunol 149:977\u2013987e914. https:\/\/doi.org\/10.1016\/j.jaci.2021.07.036","journal-title":"J Allergy Clin Immunol"},{"key":"9115_CR268","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1001\/jamadermatol.2021.3023","volume":"157","author":"A Blauvelt","year":"2021","unstructured":"Blauvelt A et al (2021) Efficacy and safety of Upadacitinib vs dupilumab in adults with moderate-to-severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol 157:1047\u20131055. https:\/\/doi.org\/10.1001\/jamadermatol.2021.3023","journal-title":"JAMA Dermatol"},{"key":"9115_CR269","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1093\/bjd\/ljae404","volume":"192","author":"JI Silverberg","year":"2024","unstructured":"Silverberg JI et al (2024) Efficacy and safety of upadacitinib versus dupilumab in adults and adolescents with moderate-to-severe atopic dermatitis: week 16 results of an open-label randomized efficacy assessor-blinded head-to-head phase IIIb\/IV study (Level Up). Br J Dermatol 192:36\u201345. https:\/\/doi.org\/10.1093\/bjd\/ljae404","journal-title":"Br J Dermatol"},{"key":"9115_CR270","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1089\/derm.2023.0132","volume":"35","author":"D Huang","year":"2024","unstructured":"Huang D, Lu J, Tan F (2024) Improvement of pruritus and efficacy in the early stage of therapy with Upadacitinib, Abrocitinib, or dupilumab in Chinese patients with moderate-to-severe atopic dermatitis: prospective, cohort, observational study. Dermatitis 35:77\u201383. https:\/\/doi.org\/10.1089\/derm.2023.0132","journal-title":"Dermatitis"},{"key":"9115_CR271","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1001\/jamadermatol.2023.0391","volume":"159","author":"AS Paller","year":"2023","unstructured":"Paller AS et al (2023) Efficacy and safety of upadacitinib treatment in adolescents with moderate-to-severe atopic dermatitis: analysis of the measure up 1, measure up 2, and AD up randomized clinical trials. JAMA Dermatol 159:526\u2013535. https:\/\/doi.org\/10.1001\/jamadermatol.2023.0391","journal-title":"JAMA Dermatol"},{"key":"9115_CR272","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2022-002735","author":"GR Burmester","year":"2023","unstructured":"Burmester GR et al (2023) Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis. RMD Open. https:\/\/doi.org\/10.1136\/rmdopen-2022-002735","journal-title":"RMD Open"},{"key":"9115_CR273","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/j.jaad.2018.01.018","volume":"80","author":"E Guttman-Yassky","year":"2019","unstructured":"Guttman-Yassky E et al (2019) Baricitinib in adult patients with moderate-to-severe atopic dermatitis: A phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study. J Am Acad Dermatol 80:913\u2013921e919. https:\/\/doi.org\/10.1016\/j.jaad.2018.01.018","journal-title":"J Am Acad Dermatol"},{"key":"9115_CR274","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1111\/bjd.18898","volume":"183","author":"EL Simpson","year":"2020","unstructured":"Simpson EL et al (2020) Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials. Br J Dermatol 183:242\u2013255. https:\/\/doi.org\/10.1111\/bjd.18898","journal-title":"Br J Dermatol"},{"key":"9115_CR275","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1001\/jamadermatol.2020.3260","volume":"156","author":"K Reich","year":"2020","unstructured":"Reich K et al (2020) Efficacy and safety of baricitinib combined with topical corticosteroids for treatment of moderate to severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol 156:1333\u20131343. https:\/\/doi.org\/10.1001\/jamadermatol.2020.3260","journal-title":"JAMA Dermatol"},{"key":"9115_CR276","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1001\/jamadermatol.2021.1273","volume":"157","author":"JI Silverberg","year":"2021","unstructured":"Silverberg JI et al (2021) Long-term efficacy of baricitinib in adults with moderate to severe atopic dermatitis who were treatment responders or partial responders: an extension study of 2 randomized clinical trials. JAMA Dermatol 157:691\u2013699. https:\/\/doi.org\/10.1001\/jamadermatol.2021.1273","journal-title":"JAMA Dermatol"},{"key":"9115_CR277","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1111\/jdv.18816","volume":"37","author":"JI Silverberg","year":"2023","unstructured":"Silverberg JI et al (2023) Long-term efficacy (up to 68 weeks) of Baricitinib in combination with topical corticosteroids in adult patients with moderate-to-severe atopic dermatitis: analysis of treatment responders, partial responders and nonresponders originating from study BREEZE-AD7. J Eur Acad Dermatol Venereol 37:1036\u20131045. https:\/\/doi.org\/10.1111\/jdv.18816","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"9115_CR278","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1093\/bjd\/ljac057","volume":"188","author":"K Reich","year":"2023","unstructured":"Reich K et al (2023) Efficacy of downtitration or treatment withdrawal compared with continuous dosing after successful treatment with baricitinib in patients with moderate-to-severe atopic dermatitis in a randomized substudy from the long-term extension study BREEZE-AD3. Br J Dermatol 188:208\u2013217. https:\/\/doi.org\/10.1093\/bjd\/ljac057","journal-title":"Br J Dermatol"},{"key":"9115_CR279","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2023.2190430","volume":"34","author":"JP Thyssen","year":"2023","unstructured":"Thyssen JP et al (2023) Maintained improvement in physician- and patient-reported outcomes with baricitinib in adults with moderate-to-severe atopic dermatitis who were treated for up to 104 weeks in a randomized trial. J Dermatolog Treat 34:2190430. https:\/\/doi.org\/10.1080\/09546634.2023.2190430","journal-title":"J Dermatolog Treat"},{"key":"9115_CR280","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1007\/s40257-021-00627-2","volume":"22","author":"Y Zhao","year":"2021","unstructured":"Zhao Y et al (2021) Efficacy and safety of SHR0302, a highly selective Janus kinase 1 inhibitor, in patients with moderate to severe atopic dermatitis: a phase II randomized clinical trial. Am J Clin Dermatol 22:877\u2013889. https:\/\/doi.org\/10.1007\/s40257-021-00627-2","journal-title":"Am J Clin Dermatol"},{"key":"9115_CR281","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1111\/bjd.17932","volume":"181","author":"R Bissonnette","year":"2019","unstructured":"Bissonnette R et al (2019) The oral Janus kinase\/spleen tyrosine kinase inhibitor ASN002 demonstrates efficacy and improves associated systemic inflammation in patients with moderate-to-severe atopic dermatitis: results from a randomized double-blind placebo-controlled study. Br J Dermatol 181:733\u2013742. https:\/\/doi.org\/10.1111\/bjd.17932","journal-title":"Br J Dermatol"},{"key":"9115_CR282","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1016\/j.jaci.2023.08.029","volume":"152","author":"AWL Chu","year":"2023","unstructured":"Chu AWL et al (2023) Systemic treatments for atopic dermatitis (eczema): systematic review and network meta-analysis of randomized trials. J Allergy Clin Immunol 152:1470\u20131492. https:\/\/doi.org\/10.1016\/j.jaci.2023.08.029","journal-title":"J Allergy Clin Immunol"},{"key":"9115_CR283","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1016\/j.jaci.2023.08.030","volume":"152","author":"DK Chu","year":"2023","unstructured":"Chu DK et al (2023) Topical treatments for atopic dermatitis (eczema): systematic review and network meta-analysis of randomized trials. J Allergy Clin Immunol 152:1493\u20131519. https:\/\/doi.org\/10.1016\/j.jaci.2023.08.030","journal-title":"J Allergy Clin Immunol"},{"issue":"8","key":"9115_CR284","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD015064.pub2","volume":"2024","author":"SJ Lax","year":"2024","unstructured":"Lax SJ et al (2024) Topical anti-inflammatory treatments for eczema: network meta-analysis. Cochrane Database Syst Rev (8):Cd015064. https:\/\/doi.org\/10.1002\/14651858.CD015064.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"9115_CR285","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/s0140-6736(22)02037-2","volume":"401","author":"E Guttman-Yassky","year":"2023","unstructured":"Guttman-Yassky E et al (2023) An anti-OX40 antibody to treat moderate-to-severe atopic dermatitis: a multicentre, double-blind, placebo-controlled phase 2b study. Lancet 401:204\u2013214. https:\/\/doi.org\/10.1016\/s0140-6736(22)02037-2","journal-title":"Lancet"},{"key":"9115_CR286","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1016\/j.jaci.2024.10.031","volume":"155","author":"S Weidinger","year":"2025","unstructured":"Weidinger S et al (2025) Phase 2b randomized clinical trial of amlitelimab, an anti-OX40 ligand antibody, in patients with moderate-to-severe atopic dermatitis. J Allergy Clin Immunol 155:1264\u20131275. https:\/\/doi.org\/10.1016\/j.jaci.2024.10.031","journal-title":"J Allergy Clin Immunol"},{"key":"9115_CR287","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1111\/bjd.17455","volume":"180","author":"YW Lee","year":"2019","unstructured":"Lee YW et al (2019) Efficacy and safety of PAC-14028 cream - a novel, topical, nonsteroidal, selective TRPV1 antagonist in patients with mild-to-moderate atopic dermatitis: a phase IIb randomized trial. Br J Dermatol 180:1030\u20131038. https:\/\/doi.org\/10.1111\/bjd.17455","journal-title":"Br J Dermatol"},{"key":"9115_CR288","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1016\/j.jaci.2021.09.024","volume":"149","author":"CW Park","year":"2022","unstructured":"Park CW et al (2022) Asivatrep, a TRPV1 antagonist, for the topical treatment of atopic dermatitis: phase 3, randomized, vehicle-controlled study (CAPTAIN-AD). J Allergy Clin Immunol 149:1340\u20131347e1344. https:\/\/doi.org\/10.1016\/j.jaci.2021.09.024","journal-title":"J Allergy Clin Immunol"},{"key":"9115_CR289","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1016\/j.jaci.2023.06.023","volume":"152","author":"E Guttman-Yassky","year":"2023","unstructured":"Guttman-Yassky E et al (2023) Oral difelikefalin reduces moderate to severe pruritus and expression of pruritic and inflammatory biomarkers in subjects with atopic dermatitis. J Allergy Clin Immunol 152:916\u2013926. https:\/\/doi.org\/10.1016\/j.jaci.2023.06.023","journal-title":"J Allergy Clin Immunol"},{"key":"9115_CR290","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1007\/s00011-023-01724-0","volume":"72","author":"Y Jiang","year":"2023","unstructured":"Jiang Y et al (2023) Curcumin inhibits the pruritus in mice through mast cell MrgprB2 receptor. Inflamm Res 72:933\u2013945. https:\/\/doi.org\/10.1007\/s00011-023-01724-0","journal-title":"Inflamm Res"},{"key":"9115_CR291","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1002\/ptr.6531","volume":"34","author":"J Wang","year":"2020","unstructured":"Wang J et al (2020) Paeoniflorin inhibits MRGPRX2-mediated pseudo-allergic reaction via calcium signaling pathway. Phytother Res 34:401\u2013408. https:\/\/doi.org\/10.1002\/ptr.6531","journal-title":"Phytother Res"},{"key":"9115_CR292","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1093\/jpp\/rgad056","volume":"75","author":"Y Zhang","year":"2023","unstructured":"Zhang Y et al (2023) Fisetin alleviates chronic urticaria by inhibiting mast cell activation via MRGPRX2. J Pharm Pharmacol 75:1310\u20131321. https:\/\/doi.org\/10.1093\/jpp\/rgad056","journal-title":"J Pharm Pharmacol"},{"key":"9115_CR293","doi-asserted-by":"publisher","first-page":"806","DOI":"10.3892\/ijmm.2020.4633","volume":"46","author":"Y Di","year":"2020","unstructured":"Di Y et al (2020) Ursolic acid protects against cisplatin\u2011induced ototoxicity by inhibiting oxidative stress and TRPV1\u2011mediated Ca2+\u2011signaling. Int J Mol Med 46:806\u2013816. https:\/\/doi.org\/10.3892\/ijmm.2020.4633","journal-title":"Int J Mol Med"},{"key":"9115_CR294","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1016\/j.jaci.2022.12.805","volume":"151","author":"M Kumar","year":"2023","unstructured":"Kumar M, Duraisamy K, Annapureddy RR, Chan CB, Chow BKC (2023) Novel small molecule MRGPRX2 antagonists inhibit a murine model of allergic reaction. J Allergy Clin Immunol 151:1110\u20131122. https:\/\/doi.org\/10.1016\/j.jaci.2022.12.805","journal-title":"J Allergy Clin Immunol"},{"key":"9115_CR295","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1406438","volume":"15","author":"TK Wong","year":"2024","unstructured":"Wong TK, Choi YG, Li PH, Chow BKC, Kumar M (2024) MRGPRX2 antagonist GE1111 attenuated DNFB-induced atopic dermatitis in mice by reducing inflammatory cytokines and restoring skin integrity. Front Immunol 15:1406438. https:\/\/doi.org\/10.3389\/fimmu.2024.1406438","journal-title":"Front Immunol"},{"key":"9115_CR296","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/j.jaci.2024.07.002","volume":"154","author":"J Wollam","year":"2024","unstructured":"Wollam J et al (2024) Inhibition of mast cell degranulation by novel small molecule MRGPRX2 antagonists. J Allergy Clin Immunol 154:1033\u20131043. https:\/\/doi.org\/10.1016\/j.jaci.2024.07.002","journal-title":"J Allergy Clin Immunol"},{"key":"9115_CR297","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2022.109063","volume":"110","author":"D Che","year":"2022","unstructured":"Che D et al (2022) Clarithromycin-treated chronic spontaneous urticaria with the negative regulation of Fc\u03b5R\u0399 and MRGPRX2 activation via CD300f. Int Immunopharmacol 110:109063. https:\/\/doi.org\/10.1016\/j.intimp.2022.109063","journal-title":"Int Immunopharmacol"},{"key":"9115_CR298","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1033794","volume":"13","author":"M Bawazir","year":"2022","unstructured":"Bawazir M, Amponnawarat A, Hui Y, Oskeritzian CA, Ali H (2022) Inhibition of MRGPRX2 but not Fc\u03b5RI or MrgprB2-mediated mast cell degranulation by a small molecule inverse receptor agonist. Front Immunol 13:1033794. https:\/\/doi.org\/10.3389\/fimmu.2022.1033794","journal-title":"Front Immunol"},{"key":"9115_CR299","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellimm.2023.104728","volume":"388\u2013389","author":"Y Ding","year":"2023","unstructured":"Ding Y et al (2023) Paeonol attenuates Substance P-induced urticaria by inhibiting Src kinase phosphorylation in mast cells. Cell Immunol 388\u2013389:104728. https:\/\/doi.org\/10.1016\/j.cellimm.2023.104728","journal-title":"Cell Immunol"},{"key":"9115_CR300","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2020.153391","volume":"80","author":"Y Ding","year":"2021","unstructured":"Ding Y et al (2021) \u03b1-Linolenic acid attenuates pseudo-allergic reactions by inhibiting Lyn kinase activity. Phytomedicine 80:153391. https:\/\/doi.org\/10.1016\/j.phymed.2020.153391","journal-title":"Phytomedicine"},{"key":"9115_CR301","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2022.109437","volume":"113","author":"Y Ding","year":"2022","unstructured":"Ding Y, Dang B, Wang Y, Zhao C, An H (2022) Artemisinic acid attenuated symptoms of substance P-induced chronic urticaria in a mice model and mast cell degranulation via Lyn\/PLC-p38 signal pathway. Int Immunopharmacol 113:109437. https:\/\/doi.org\/10.1016\/j.intimp.2022.109437","journal-title":"Int Immunopharmacol"},{"key":"9115_CR302","doi-asserted-by":"publisher","first-page":"803335","DOI":"10.3389\/fimmu.2021.803335","volume":"12","author":"S Chaki","year":"2021","unstructured":"Chaki S et al (2021) Inhibition of Orai channel function regulates Mas-Related G Protein-Coupled Receptor-Mediated responses in mast cells. Front Immunol 12:803335. https:\/\/doi.org\/10.3389\/fimmu.2021.803335","journal-title":"Front Immunol"},{"key":"9115_CR303","doi-asserted-by":"publisher","DOI":"10.3390\/cells10020450","author":"E Manzo","year":"2021","unstructured":"Manzo E et al (2021) A glucuronic acid-palmitoylethanolamide conjugate (GLUPEA) is an innovative drug delivery system and a potential bioregulator. Cells. https:\/\/doi.org\/10.3390\/cells10020450","journal-title":"Cells"},{"key":"9115_CR304","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2024.118580","volume":"334","author":"T Yan","year":"2024","unstructured":"Yan T et al (2024) Artemisia argyi volatile oil ameliorates allergic contact dermatitis via modulating TRPA1\/CGRP signaling. J Ethnopharmacol 334:118580. https:\/\/doi.org\/10.1016\/j.jep.2024.118580","journal-title":"J Ethnopharmacol"},{"key":"9115_CR305","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1111\/all.15998","volume":"79","author":"Y Xu","year":"2024","unstructured":"Xu Y et al (2024) Propionate alleviates itch in murine models of atopic dermatitis by modulating sensory TRP channels of dorsal root ganglion. Allergy 79:1271\u20131290. https:\/\/doi.org\/10.1111\/all.15998","journal-title":"Allergy"},{"key":"9115_CR306","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15199","volume":"33","author":"L Misery","year":"2019","unstructured":"Misery L et al (2019) Real-life study of anti-itching effects of a cream containing menthoxypropanediol, a TRPM8 agonist, in atopic dermatitis patients. J Eur Acad Dermatol Venereol 33:e67-e69. https:\/\/doi.org\/10.1111\/jdv.15199","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"9115_CR307","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1111\/bph.16012","volume":"180","author":"PY Sun","year":"2023","unstructured":"Sun PY et al (2023) Lidocaine alleviates inflammation and pruritus in atopic dermatitis by blocking different population of sensory neurons. Br J Pharmacol 180:1339\u20131361. https:\/\/doi.org\/10.1111\/bph.16012","journal-title":"Br J Pharmacol"},{"key":"9115_CR308","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.jdermsci.2007.05.006","volume":"47","author":"J Jiang","year":"2007","unstructured":"Jiang J et al (2007) Inhibitory effects of paroxetine on the development of atopic dermatitis-like lesions in NC\/Nga mice. J Dermatol Sci 47:244\u2013247. https:\/\/doi.org\/10.1016\/j.jdermsci.2007.05.006","journal-title":"J Dermatol Sci"},{"key":"9115_CR309","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2016.00318","volume":"7","author":"Y Li","year":"2016","unstructured":"Li Y et al (2016) Fluoxetine ameliorates atopic dermatitis-like skin lesions in BALB\/c mice through reducing psychological stress and inflammatory response. Front Pharmacol 7:318. https:\/\/doi.org\/10.3389\/fphar.2016.00318","journal-title":"Front Pharmacol"},{"key":"9115_CR310","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2019.153137","volume":"67","author":"SH Park","year":"2020","unstructured":"Park SH, Jang S, An JE, Choo BK, Kim HK (2020) I. inflexus (Thunb.) Kudo extract improves atopic dermatitis and depressive-like behavior in DfE-induced atopic dermatitis-like disease. Phytomedicine 67:153137. https:\/\/doi.org\/10.1016\/j.phymed.2019.153137","journal-title":"Phytomedicine"},{"key":"9115_CR311","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18010190","author":"B Sur","year":"2017","unstructured":"Sur B et al (2017) Extract of Polygala tenuifolia alleviates stress-exacerbated atopy-like skin dermatitis through the modulation of protein kinase A and p38 mitogen-activated protein kinase signaling pathway. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms18010190","journal-title":"Int J Mol Sci"},{"key":"9115_CR312","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbi.2021.109564","volume":"345","author":"CAR da Fonseca","year":"2021","unstructured":"da Fonseca CAR et al (2021) Bis-(3-amino-2-pyridine) diselenide improves psychiatric disorders -atopic dermatitis comorbidity by regulating inflammatory and oxidative status in mice. Chem Biol Interact 345:109564. https:\/\/doi.org\/10.1016\/j.cbi.2021.109564","journal-title":"Chem Biol Interact"},{"key":"9115_CR313","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.663417","volume":"12","author":"MJ Balgoon","year":"2021","unstructured":"Balgoon MJ, Al-Zahrani MH, Jaouni SA, Ayuob N (2021) Combined oral and topical application of pumpkin (Cucurbita pepo L.) alleviates contact dermatitis associated with depression through downregulation pro-inflammatory cytokines. Front Pharmacol 12:663417. https:\/\/doi.org\/10.3389\/fphar.2021.663417","journal-title":"Front Pharmacol"}],"container-title":["Clinical Reviews in Allergy & Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-025-09115-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12016-025-09115-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-025-09115-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T12:11:14Z","timestamp":1765973474000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12016-025-09115-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,17]]},"references-count":313,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["9115"],"URL":"https:\/\/doi.org\/10.1007\/s12016-025-09115-5","relation":{},"ISSN":["1559-0267"],"issn-type":[{"value":"1559-0267","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,17]]},"assertion":[{"value":"6 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"107"}}